introduction on dementia essay

A cultural approach to dementia prevention

• An Introduction to Alzheimer’s Disease: What is it?

By: Adrianna Fusco

Introduction: Alzheimer’s disease, something we hear about online, in commercials, on news stations, and in many other parts of life. However, we are never told much about Alzheimer’s disease other than the devastating impacts it has. What is Alzheimer’s disease? What are the symptoms or signs to look out for? How does it progress? What causes it? How can it be prevented?

What is it? Alzheimer’s disease is a form of dementia, which is just an umbrella term used to describe loss of memory, language, problem solving, and other thinking abilities. More specifically, Alzheimer’s diseaseis a progressive, neurodegenerative disease that is categorized by a loss of memory, along with basic life skills like eating, bathing, talking, etc.

Symptoms: Common symptoms include: memory loss, paranoia, depression, anger, aggression, anxiety, apathy, loneliness, and psychosis. These symptoms vary from person to person.

Progress: As mentioned above, Alzheimer’s disease is a progressive disease. This means that it develops and gets worse over time. In the first stages of Alzheimer’s disease, there is usually very mild memory loss or problems with thinking abilities. The person may have a hard time remembering where they placed something or have a hard time recalling the right word to say. However, they still are independent, meaning they can still take care of themselves and do things like driving.

During the middle stages of Alzheimer’s disease, the cognitive processes get worse. Now the person may not be able to remember their personal history, like their address or phone number. They also may have a hard time recalling memories or remembering something from their past. The person is no longer able to take care of themselves because in this stage, they tend to forget where they are and often have a hard time using the bathroom or getting dressed appropriately for the day. An example of this is the person wearing shorts in the winter. Along with the cognitive changes, the person may begin to feel sad, lonely, anxious, and paranoid. The symptoms vary from person to person.

When the person hits stage 2, they will need a caregiver to assist them with their tasks and the caregiving will increase as the disease progresses. However, it’s important to help them without trying to do everything for them. They are still adults and they want to be treated as such, so it’s important to still let them have at least some control over their life. Whether that’s letting them do simply chores, like folding clothes, or doing activities, like arts and crafts. This will help provide a sense of normalcy.

The final stage of Alzheimer’s disease is when people begin to lose sense and control of the environment around them. By this point, the cognitive abilities of the individual have tremendously decreased. They can no longer speak in long formulated sentences, instead they speak in short fragments or words. They have trouble completing everyday tasks like walking, sitting, eating, and drinking. This means that they require around the clock assistance to make sure that they are remembering to eat and to help them eat. In general, the assistance is meant to make sure the person is safe and is living to their best ability. At this point, the individuals are very susceptible to infections. When the symptoms and daily conditions get really bad, usually, families turn to hospice care, so that the patient is comfortable at the end of their life. Hospice care also provides emotional support to loved ones, which is vital. Losing a loved one can cause serious emotional and mental strain, so that support is important.

The cause of Alzheimer’s disease is still being researched, but researchers have identified what they believe to be the main culprits of the disease: plaques and tangles. 

Plaques are deposits of amyloid beta that forms between nerve cells that blocks the signals and stops the right materials from being sent to the nerve for survival. In a healthy brain, amyloid beta is used to help support neural repair and growth. However, in Alzheimer’s disease, there is an overproduction of this amyloid beta protein that disturbs these cells and eventually causes the death of the cells. The death of the old cells causes the loss of old memories and information. The blocking of nerve cells can stop the production of new connections, which means short term memories are not being accurately encoded in the brain to become long term memories. 

Tangles are made up of twisted tau that builds up between cells. In a healthy brain, tau is used to help support neural strength and is important in keeping stability in the cells. However, a build up leads to the cells not being able to receive signals and the supplies it needs to function (i.e. energy). These lead to death of the cells, leading to loss of information and life skills.

There is also a biomarker known as APOE-4, that is thought to predispose people to Alzheimer’s disease. This gene along with some environmental stressors could affect whether someone gets the disease and the progression of it. However, a lot of research is still being conducted on this topic and we are constantly rerouting what we know, as new information is found.

Alzheimer’s disease is a terrible disease that claims the lives of a lot of people every year. It’s important to know the signs and to check up with your doctor when anything seems unusual. Alzheimer’s disease and dementia are not a normal part of aging, so see your doctor if you notice any issues with your memory. The earlier the disease is detected, the better it can be treated.

Stay tuned for more blog posts about Alzheimer’s disease, including a look into the mental health of caregivers, prevention, treatment, and more! We also will be writing posts about interviews with doctors, as well as posts about brain health!

Thank you for reading!

References: 

“Alzheimer’s Caregivers: 8 Tips for People Caring for a Loved One With Alzheimer’s Disease or Dementia: Caregivers.” 30Seconds Health , 

30seconds.com/health/tip/14389/Alzheimers-Caregivers-8-Tips-for-People-Caring-for-a-Loved-One-With -Alzheimers-Disease-or-Dementia. 

Mayeux, Richard, et al. “Treatment of Alzheimer’s Disease: NEJM.” Edited by Alastair J.J. Wood, New England Journal of Medicine , 16 Mar. 2000, www.nejm.org/doi/pdf/10.1056/NEJM199911253412207. 

NHS Choices, NHS, 10 May 2018, 

www.nhs.uk/conditions/alzheimers-disease/causes/#:~:text=Alzheimer’s%20disease%20is%20thought%2 0to,form%20tangles%20within%20brain%20cells. 

Porsteinsson, Anton P., et al. “Neuropsychiatric Symptoms in Dementia: A Cause or Consequence?” American Journal of Psychiatry , American Psychiatric Association Publishing, 30 Apr. 2015, ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2015.15030277#:~:text=The%20term%20neuropsychiatric %20symptoms%20describes%20heterogeneous%20behavioral%20or,agitation%2C%20anxiety%2C%20 apathy%2C%20depression%2C%20psychosis%2C%20and%20sleep%20disturbance. 

“Stages of Alzheimer’s.” Alzheimer’s Disease and Dementia , www.alz.org/alzheimers-dementia/stages. 

“What Is Alzheimer’s?” Alzheimer’s Disease and Dementia , 

www.alz.org/alzheimers-dementia/what-is-alzheimers.

An Introduction to Dementia

An introduction to dementia

We all know that the population is aging and that more and more older people now live with dementia.  If you work in health care there is a good chance you already know a fair amount about dementia.  However, if you are a loved one of someone recently diagnosed with dementia you may be looking for an introduction to dementia.

More and more people now offer support and care for a loved one living with dementia. There is also a growing number of people who interact or meet people living with the condition and want to know a bit more about it. There is a lot of information in the press and online, in fact so much that it can be confusing but here is a basic introduction to dementia.

What is dementia?

Whilst this is a fairly short definition it is quite technical and may still leave some people confused, so let’s unpick it a bit.

There are over 100 different types of dementia that we know about. There is a tendency to group them together when offering support and help. One of the reasons the NHS consider it to be a syndrome rather than separating out to the 100 individual diseases is that there is no accurate way of diagnosing which particular one any given individual may be living with.

Symptoms of dementia

The most widely discussed symptom of dementia is of course memory loss but there are many others. Some people find it harder to communicate, they may experience language problems and it is not uncommon for there to be some changes in personality.

Again, as listed by the NHS, here are the main symptoms of dementia:

• Memory loss
• Difficulty concentrating
• Finding it hard to carry out familiar daily tasks, such as getting confused over the correct change when shopping
• Struggling to follow a conversation or find the right word
• Confusion about time and place
• Mood changes

Initially these symptoms are often quite mild and as such family and friends may not take it that seriously or even notice. But, in most cases this will get worse and have an ever greater impact on the individual and those around them.

Sometimes a doctor will diagnose someone with ‘mild cognitive impairment’ (MCI) rather dementia at an early stage of dementia.

Dementia is a progressive condition

There is no cure for dementia but there are a number of treatments that can slow the progress and therefore slow its impact. These treatments include:

• Drugs and medicines including Acetylcholinesterase inhibitors and Memantine
• Cognitive stimulation therapy (CST) including group activities and exercises designed to improve memory, problem-solving skills and language ability
• Cognitive rehabilitation
• Reminiscence and life story work

What dementia is not

Dementia is not a normal part of ageing.

Dementia is not the occasional lapse in memory or a bit of forgetfulness; it is more severe than that.

Dementia is not just a condition that affects older people, although it is more common in older people. It also affects some younger people, although it is quite rare. When someone under 65 is diagnosed with a form of dementia, it is called ‘early onset dementia’.

Many people think Alzheimer’s disease and dementia are the same thing – they are not. Alzheimer’s is a type of dementia and the most common one. However, it is not the only one. Dementia is not a mental illness. Dementia is caused by damage to the brain from a disease. It is a physical condition not a mental one.

Worried that you or someone you love may have dementia?

If someone you know is demonstrating the above symptoms then you should encourage them to see their GP. There is a much greater chance of slowing the progress of dementia if it is diagnosed earlier.

But also, sometimes people can experience memory loss for a range of other completely treatable reasons. Either way, contacting your GP is the most sensible course of action as soon as you become worried.

This article is only an introduction to dementia, there is a great deal more to learn.  If you want to learn more then feel free to contact your closest Greensleeves Care home where the manager will be happy to help.

• Search Menu

Sign in through your institution

• Browse content in Arts and Humanities
• Browse content in Archaeology
• Anglo-Saxon and Medieval Archaeology
• Archaeological Methodology and Techniques
• Archaeology by Region
• Archaeology of Religion
• Archaeology of Trade and Exchange
• Biblical Archaeology
• Contemporary and Public Archaeology
• Environmental Archaeology
• Historical Archaeology
• History and Theory of Archaeology
• Industrial Archaeology
• Landscape Archaeology
• Mortuary Archaeology
• Prehistoric Archaeology
• Underwater Archaeology
• Zooarchaeology
• Browse content in Architecture
• Architectural Structure and Design
• History of Architecture
• Residential and Domestic Buildings
• Theory of Architecture
• Browse content in Art
• Art Subjects and Themes
• History of Art
• Industrial and Commercial Art
• Theory of Art
• Biographical Studies
• Byzantine Studies
• Browse content in Classical Studies
• Classical History
• Classical Philosophy
• Classical Mythology
• Classical Numismatics
• Classical Literature
• Classical Reception
• Classical Art and Architecture
• Classical Oratory and Rhetoric
• Greek and Roman Epigraphy
• Greek and Roman Law
• Greek and Roman Papyrology
• Greek and Roman Archaeology
• Late Antiquity
• Religion in the Ancient World
• Social History
• Digital Humanities
• Browse content in History
• Colonialism and Imperialism
• Diplomatic History
• Environmental History
• Genealogy, Heraldry, Names, and Honours
• Genocide and Ethnic Cleansing
• Historical Geography
• History by Period
• History of Emotions
• History of Agriculture
• History of Education
• History of Gender and Sexuality
• Industrial History
• Intellectual History
• International History
• Labour History
• Legal and Constitutional History
• Local and Family History
• Maritime History
• Military History
• National Liberation and Post-Colonialism
• Oral History
• Political History
• Public History
• Regional and National History
• Revolutions and Rebellions
• Slavery and Abolition of Slavery
• Social and Cultural History
• Theory, Methods, and Historiography
• Urban History
• World History
• Browse content in Language Teaching and Learning
• Language Learning (Specific Skills)
• Language Teaching Theory and Methods
• Browse content in Linguistics
• Applied Linguistics
• Cognitive Linguistics
• Computational Linguistics
• Forensic Linguistics
• Grammar, Syntax and Morphology
• Historical and Diachronic Linguistics
• History of English
• Language Acquisition
• Language Evolution
• Language Reference
• Language Variation
• Language Families
• Lexicography
• Linguistic Anthropology
• Linguistic Theories
• Linguistic Typology
• Phonetics and Phonology
• Psycholinguistics
• Sociolinguistics
• Translation and Interpretation
• Writing Systems
• Browse content in Literature
• Bibliography
• Children's Literature Studies
• Literary Studies (Asian)
• Literary Studies (European)
• Literary Studies (Eco-criticism)
• Literary Studies (Romanticism)
• Literary Studies (American)
• Literary Studies (Modernism)
• Literary Studies - World
• Literary Studies (1500 to 1800)
• Literary Studies (19th Century)
• Literary Studies (20th Century onwards)
• Literary Studies (African American Literature)
• Literary Studies (British and Irish)
• Literary Studies (Early and Medieval)
• Literary Studies (Fiction, Novelists, and Prose Writers)
• Literary Studies (Gender Studies)
• Literary Studies (Graphic Novels)
• Literary Studies (History of the Book)
• Literary Studies (Plays and Playwrights)
• Literary Studies (Poetry and Poets)
• Literary Studies (Postcolonial Literature)
• Literary Studies (Queer Studies)
• Literary Studies (Science Fiction)
• Literary Studies (Travel Literature)
• Literary Studies (War Literature)
• Literary Studies (Women's Writing)
• Literary Theory and Cultural Studies
• Mythology and Folklore
• Shakespeare Studies and Criticism
• Browse content in Media Studies
• Browse content in Music
• Applied Music
• Dance and Music
• Ethics in Music
• Ethnomusicology
• Gender and Sexuality in Music
• Medicine and Music
• Music Cultures
• Music and Religion
• Music and Media
• Music and Culture
• Music Education and Pedagogy
• Music Theory and Analysis
• Musical Scores, Lyrics, and Libretti
• Musical Structures, Styles, and Techniques
• Musicology and Music History
• Performance Practice and Studies
• Race and Ethnicity in Music
• Sound Studies
• Browse content in Performing Arts
• Browse content in Philosophy
• Aesthetics and Philosophy of Art
• Epistemology
• Feminist Philosophy
• History of Western Philosophy
• Metaphysics
• Moral Philosophy
• Non-Western Philosophy
• Philosophy of Science
• Philosophy of Language
• Philosophy of Mind
• Philosophy of Perception
• Philosophy of Action
• Philosophy of Law
• Philosophy of Religion
• Philosophy of Mathematics and Logic
• Practical Ethics
• Social and Political Philosophy
• Browse content in Religion
• Biblical Studies
• Christianity
• East Asian Religions
• History of Religion
• Judaism and Jewish Studies
• Qumran Studies
• Religion and Education
• Religion and Health
• Religion and Politics
• Religion and Science
• Religion and Law
• Religion and Art, Literature, and Music
• Religious Studies
• Browse content in Society and Culture
• Cookery, Food, and Drink
• Cultural Studies
• Customs and Traditions
• Ethical Issues and Debates
• Hobbies, Games, Arts and Crafts
• Natural world, Country Life, and Pets
• Popular Beliefs and Controversial Knowledge
• Sports and Outdoor Recreation
• Technology and Society
• Travel and Holiday
• Visual Culture
• Browse content in Law
• Arbitration
• Browse content in Company and Commercial Law
• Commercial Law
• Company Law
• Browse content in Comparative Law
• Systems of Law
• Competition Law
• Browse content in Constitutional and Administrative Law
• Government Powers
• Judicial Review
• Local Government Law
• Military and Defence Law
• Parliamentary and Legislative Practice
• Construction Law
• Contract Law
• Browse content in Criminal Law
• Criminal Procedure
• Criminal Evidence Law
• Sentencing and Punishment
• Employment and Labour Law
• Environment and Energy Law
• Browse content in Financial Law
• Banking Law
• Insolvency Law
• History of Law
• Human Rights and Immigration
• Intellectual Property Law
• Browse content in International Law
• Private International Law and Conflict of Laws
• Public International Law
• IT and Communications Law
• Jurisprudence and Philosophy of Law
• Law and Politics
• Law and Society
• Browse content in Legal System and Practice
• Courts and Procedure
• Legal Skills and Practice
• Legal System - Costs and Funding
• Primary Sources of Law
• Regulation of Legal Profession
• Medical and Healthcare Law
• Browse content in Policing
• Criminal Investigation and Detection
• Police and Security Services
• Police Procedure and Law
• Police Regional Planning
• Browse content in Property Law
• Personal Property Law
• Restitution
• Study and Revision
• Terrorism and National Security Law
• Browse content in Trusts Law
• Wills and Probate or Succession
• Browse content in Medicine and Health
• Browse content in Allied Health Professions
• Arts Therapies
• Clinical Science
• Dietetics and Nutrition
• Occupational Therapy
• Operating Department Practice
• Physiotherapy
• Radiography
• Speech and Language Therapy
• Browse content in Anaesthetics
• General Anaesthesia
• Browse content in Clinical Medicine
• Acute Medicine
• Cardiovascular Medicine
• Clinical Genetics
• Clinical Pharmacology and Therapeutics
• Dermatology
• Endocrinology and Diabetes
• Gastroenterology
• Genito-urinary Medicine
• Geriatric Medicine
• Infectious Diseases
• Medical Toxicology
• Medical Oncology
• Pain Medicine
• Palliative Medicine
• Rehabilitation Medicine
• Respiratory Medicine and Pulmonology
• Rheumatology
• Sleep Medicine
• Sports and Exercise Medicine
• Clinical Neuroscience
• Community Medical Services
• Critical Care
• Emergency Medicine
• Forensic Medicine
• Haematology
• History of Medicine
• Browse content in Medical Dentistry
• Oral and Maxillofacial Surgery
• Paediatric Dentistry
• Restorative Dentistry and Orthodontics
• Surgical Dentistry
• Browse content in Medical Skills
• Clinical Skills
• Communication Skills
• Nursing Skills
• Surgical Skills
• Medical Ethics
• Medical Statistics and Methodology
• Browse content in Neurology
• Clinical Neurophysiology
• Neuropathology
• Nursing Studies
• Browse content in Obstetrics and Gynaecology
• Gynaecology
• Occupational Medicine
• Ophthalmology
• Otolaryngology (ENT)
• Browse content in Paediatrics
• Neonatology
• Browse content in Pathology
• Chemical Pathology
• Clinical Cytogenetics and Molecular Genetics
• Histopathology
• Medical Microbiology and Virology
• Patient Education and Information
• Browse content in Pharmacology
• Psychopharmacology
• Browse content in Popular Health
• Caring for Others
• Complementary and Alternative Medicine
• Self-help and Personal Development
• Browse content in Preclinical Medicine
• Cell Biology
• Molecular Biology and Genetics
• Reproduction, Growth and Development
• Primary Care
• Professional Development in Medicine
• Browse content in Psychiatry
• Addiction Medicine
• Child and Adolescent Psychiatry
• Forensic Psychiatry
• Learning Disabilities
• Old Age Psychiatry
• Psychotherapy
• Browse content in Public Health and Epidemiology
• Epidemiology
• Public Health
• Browse content in Radiology
• Clinical Radiology
• Interventional Radiology
• Nuclear Medicine
• Radiation Oncology
• Reproductive Medicine
• Browse content in Surgery
• Cardiothoracic Surgery
• Gastro-intestinal and Colorectal Surgery
• General Surgery
• Neurosurgery
• Paediatric Surgery
• Peri-operative Care
• Plastic and Reconstructive Surgery
• Surgical Oncology
• Transplant Surgery
• Trauma and Orthopaedic Surgery
• Vascular Surgery
• Browse content in Science and Mathematics
• Browse content in Biological Sciences
• Aquatic Biology
• Biochemistry
• Bioinformatics and Computational Biology
• Developmental Biology
• Ecology and Conservation
• Evolutionary Biology
• Genetics and Genomics
• Microbiology
• Molecular and Cell Biology
• Natural History
• Plant Sciences and Forestry
• Research Methods in Life Sciences
• Structural Biology
• Systems Biology
• Zoology and Animal Sciences
• Browse content in Chemistry
• Analytical Chemistry
• Computational Chemistry
• Crystallography
• Environmental Chemistry
• Industrial Chemistry
• Inorganic Chemistry
• Materials Chemistry
• Medicinal Chemistry
• Mineralogy and Gems
• Organic Chemistry
• Physical Chemistry
• Polymer Chemistry
• Study and Communication Skills in Chemistry
• Theoretical Chemistry
• Browse content in Computer Science
• Artificial Intelligence
• Computer Architecture and Logic Design
• Game Studies
• Human-Computer Interaction
• Mathematical Theory of Computation
• Programming Languages
• Software Engineering
• Systems Analysis and Design
• Virtual Reality
• Browse content in Computing
• Business Applications
• Computer Security
• Computer Games
• Computer Networking and Communications
• Digital Lifestyle
• Graphical and Digital Media Applications
• Operating Systems
• Browse content in Earth Sciences and Geography
• Atmospheric Sciences
• Environmental Geography
• Geology and the Lithosphere
• Maps and Map-making
• Meteorology and Climatology
• Oceanography and Hydrology
• Palaeontology
• Physical Geography and Topography
• Regional Geography
• Soil Science
• Urban Geography
• Browse content in Engineering and Technology
• Agriculture and Farming
• Biological Engineering
• Civil Engineering, Surveying, and Building
• Electronics and Communications Engineering
• Energy Technology
• Engineering (General)
• Environmental Science, Engineering, and Technology
• History of Engineering and Technology
• Mechanical Engineering and Materials
• Technology of Industrial Chemistry
• Transport Technology and Trades
• Browse content in Environmental Science
• Applied Ecology (Environmental Science)
• Conservation of the Environment (Environmental Science)
• Environmental Sustainability
• Environmentalist Thought and Ideology (Environmental Science)
• Management of Land and Natural Resources (Environmental Science)
• Natural Disasters (Environmental Science)
• Nuclear Issues (Environmental Science)
• Pollution and Threats to the Environment (Environmental Science)
• Social Impact of Environmental Issues (Environmental Science)
• History of Science and Technology
• Browse content in Materials Science
• Ceramics and Glasses
• Composite Materials
• Metals, Alloying, and Corrosion
• Nanotechnology
• Browse content in Mathematics
• Applied Mathematics
• Biomathematics and Statistics
• History of Mathematics
• Mathematical Education
• Mathematical Finance
• Mathematical Analysis
• Numerical and Computational Mathematics
• Probability and Statistics
• Pure Mathematics
• Browse content in Neuroscience
• Cognition and Behavioural Neuroscience
• Development of the Nervous System
• Disorders of the Nervous System
• History of Neuroscience
• Invertebrate Neurobiology
• Molecular and Cellular Systems
• Neuroendocrinology and Autonomic Nervous System
• Neuroscientific Techniques
• Sensory and Motor Systems
• Browse content in Physics
• Astronomy and Astrophysics
• Atomic, Molecular, and Optical Physics
• Biological and Medical Physics
• Classical Mechanics
• Computational Physics
• Condensed Matter Physics
• Electromagnetism, Optics, and Acoustics
• History of Physics
• Mathematical and Statistical Physics
• Measurement Science
• Nuclear Physics
• Particles and Fields
• Plasma Physics
• Quantum Physics
• Relativity and Gravitation
• Semiconductor and Mesoscopic Physics
• Browse content in Psychology
• Affective Sciences
• Clinical Psychology
• Cognitive Psychology
• Cognitive Neuroscience
• Criminal and Forensic Psychology
• Developmental Psychology
• Educational Psychology
• Evolutionary Psychology
• Health Psychology
• History and Systems in Psychology
• Music Psychology
• Neuropsychology
• Organizational Psychology
• Psychological Assessment and Testing
• Psychology of Human-Technology Interaction
• Psychology Professional Development and Training
• Research Methods in Psychology
• Social Psychology
• Browse content in Social Sciences
• Browse content in Anthropology
• Anthropology of Religion
• Human Evolution
• Medical Anthropology
• Physical Anthropology
• Regional Anthropology
• Social and Cultural Anthropology
• Theory and Practice of Anthropology
• Browse content in Business and Management
• Business Strategy
• Business Ethics
• Business History
• Business and Government
• Business and Technology
• Business and the Environment
• Comparative Management
• Corporate Governance
• Corporate Social Responsibility
• Entrepreneurship
• Health Management
• Human Resource Management
• Industrial and Employment Relations
• Industry Studies
• Information and Communication Technologies
• International Business
• Knowledge Management
• Management and Management Techniques
• Operations Management
• Organizational Theory and Behaviour
• Pensions and Pension Management
• Public and Nonprofit Management
• Social Issues in Business and Management
• Strategic Management
• Supply Chain Management
• Browse content in Criminology and Criminal Justice
• Criminal Justice
• Criminology
• Forms of Crime
• International and Comparative Criminology
• Youth Violence and Juvenile Justice
• Development Studies
• Browse content in Economics
• Agricultural, Environmental, and Natural Resource Economics
• Asian Economics
• Behavioural Finance
• Behavioural Economics and Neuroeconomics
• Econometrics and Mathematical Economics
• Economic Systems
• Economic History
• Economic Methodology
• Economic Development and Growth
• Financial Markets
• Financial Institutions and Services
• General Economics and Teaching
• Health, Education, and Welfare
• History of Economic Thought
• International Economics
• Labour and Demographic Economics
• Law and Economics
• Macroeconomics and Monetary Economics
• Microeconomics
• Public Economics
• Urban, Rural, and Regional Economics
• Welfare Economics
• Browse content in Education
• Adult Education and Continuous Learning
• Care and Counselling of Students
• Early Childhood and Elementary Education
• Educational Equipment and Technology
• Educational Strategies and Policy
• Higher and Further Education
• Organization and Management of Education
• Philosophy and Theory of Education
• Schools Studies
• Secondary Education
• Teaching of a Specific Subject
• Teaching of Specific Groups and Special Educational Needs
• Teaching Skills and Techniques
• Browse content in Environment
• Applied Ecology (Social Science)
• Climate Change
• Conservation of the Environment (Social Science)
• Environmentalist Thought and Ideology (Social Science)
• Management of Land and Natural Resources (Social Science)
• Natural Disasters (Environment)
• Pollution and Threats to the Environment (Social Science)
• Social Impact of Environmental Issues (Social Science)
• Sustainability
• Browse content in Human Geography
• Cultural Geography
• Economic Geography
• Political Geography
• Browse content in Interdisciplinary Studies
• Communication Studies
• Museums, Libraries, and Information Sciences
• Browse content in Politics
• African Politics
• Asian Politics
• Chinese Politics
• Comparative Politics
• Conflict Politics
• Elections and Electoral Studies
• Environmental Politics
• Ethnic Politics
• European Union
• Foreign Policy
• Gender and Politics
• Human Rights and Politics
• Indian Politics
• International Relations
• International Organization (Politics)
• Irish Politics
• Latin American Politics
• Middle Eastern Politics
• Political Methodology
• Political Communication
• Political Philosophy
• Political Sociology
• Political Behaviour
• Political Economy
• Political Institutions
• Political Theory
• Politics and Law
• Politics of Development
• Public Administration
• Public Policy
• Qualitative Political Methodology
• Quantitative Political Methodology
• Regional Political Studies
• Russian Politics
• Security Studies
• State and Local Government
• UK Politics
• US Politics
• Browse content in Regional and Area Studies
• African Studies
• Asian Studies
• East Asian Studies
• Japanese Studies
• Latin American Studies
• Middle Eastern Studies
• Native American Studies
• Scottish Studies
• Browse content in Research and Information
• Research Methods
• Browse content in Social Work
• Addictions and Substance Misuse
• Adoption and Fostering
• Care of the Elderly
• Child and Adolescent Social Work
• Couple and Family Social Work
• Direct Practice and Clinical Social Work
• Emergency Services
• Human Behaviour and the Social Environment
• International and Global Issues in Social Work
• Mental and Behavioural Health
• Social Justice and Human Rights
• Social Policy and Advocacy
• Social Work and Crime and Justice
• Social Work Macro Practice
• Social Work Practice Settings
• Social Work Research and Evidence-based Practice
• Welfare and Benefit Systems
• Browse content in Sociology
• Childhood Studies
• Community Development
• Comparative and Historical Sociology
• Disability Studies
• Economic Sociology
• Gender and Sexuality
• Gerontology and Ageing
• Health, Illness, and Medicine
• Marriage and the Family
• Migration Studies
• Occupations, Professions, and Work
• Organizations
• Population and Demography
• Race and Ethnicity
• Social Theory
• Social Movements and Social Change
• Social Research and Statistics
• Social Stratification, Inequality, and Mobility
• Sociology of Religion
• Sociology of Education
• Sport and Leisure
• Urban and Rural Studies
• Browse content in Warfare and Defence
• Defence Strategy, Planning, and Research
• Land Forces and Warfare
• Military Administration
• Military Life and Institutions
• Naval Forces and Warfare
• Other Warfare and Defence Issues
• Peace Studies and Conflict Resolution
• Weapons and Equipment

Dementia: A Very Short Introduction

Author webpage

• Cite Icon Cite
• Permissions Icon Permissions

Dementia: A Very Short Introduction explains how dementia is diagnosed, its different types and symptoms, and its effects on sufferers and their families. Why is dementia resistant to treatment? Why has the most successful scientific hypothesis not led to a cure? Are there variations between different countries, and given the rise in the ageing population, are there more or fewer cases than we think? This VSI looks at the history of dementia research and examines the genetic, physiological, and environmental risk factors and how individuals might reduce them. It also investigates developments in diagnosis and symptom management, and the economic and political context of dementia care.

Personal account

• Sign in with email/username & password
• Get email alerts
• Save searches
• Purchase content
• Activate your purchase/trial code
• Add your ORCID iD

Institutional access

Sign in with a library card.

• Sign in with username/password
• Recommend to your librarian
• Institutional account management
• Get help with access

Access to content on Oxford Academic is often provided through institutional subscriptions and purchases. If you are a member of an institution with an active account, you may be able to access content in one of the following ways:

IP based access

Typically, access is provided across an institutional network to a range of IP addresses. This authentication occurs automatically, and it is not possible to sign out of an IP authenticated account.

Choose this option to get remote access when outside your institution. Shibboleth/Open Athens technology is used to provide single sign-on between your institution’s website and Oxford Academic.

• Click Sign in through your institution.
• Select your institution from the list provided, which will take you to your institution's website to sign in.
• When on the institution site, please use the credentials provided by your institution. Do not use an Oxford Academic personal account.
• Following successful sign in, you will be returned to Oxford Academic.

If your institution is not listed or you cannot sign in to your institution’s website, please contact your librarian or administrator.

Enter your library card number to sign in. If you cannot sign in, please contact your librarian.

Society Members

Society member access to a journal is achieved in one of the following ways:

Sign in through society site

Many societies offer single sign-on between the society website and Oxford Academic. If you see ‘Sign in through society site’ in the sign in pane within a journal:

• Click Sign in through society site.
• When on the society site, please use the credentials provided by that society. Do not use an Oxford Academic personal account.

If you do not have a society account or have forgotten your username or password, please contact your society.

Sign in using a personal account

Some societies use Oxford Academic personal accounts to provide access to their members. See below.

A personal account can be used to get email alerts, save searches, purchase content, and activate subscriptions.

Some societies use Oxford Academic personal accounts to provide access to their members.

Viewing your signed in accounts

Click the account icon in the top right to:

• View your signed in personal account and access account management features.
• View the institutional accounts that are providing access.

Signed in but can't access content

Oxford Academic is home to a wide variety of products. The institutional subscription may not cover the content that you are trying to access. If you believe you should have access to that content, please contact your librarian.

For librarians and administrators, your personal account also provides access to institutional account management. Here you will find options to view and activate subscriptions, manage institutional settings and access options, access usage statistics, and more.

Our books are available by subscription or purchase to libraries and institutions.

External resource

• In the OUP print catalogue
• About Oxford Academic
• Publish journals with us
• University press partners
• What we publish
• New features  
• Open access
• Rights and permissions
• Accessibility
• Advertising
• Media enquiries
• Oxford University Press
• Oxford Languages
• University of Oxford

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide

• Copyright © 2024 Oxford University Press
• Cookie settings
• Cookie policy
• Privacy policy
• Legal notice

This Feature Is Available To Subscribers Only

Sign In or Create an Account

This PDF is available to Subscribers Only

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Presentations made painless

• Get Premium

108 Dementia Essay Topic Ideas & Examples

Inside This Article

Dementia is a complex and challenging condition that affects millions of people worldwide. Writing an essay on dementia can be a great way to raise awareness about this condition, explore its causes and symptoms, and discuss potential treatments and care strategies. However, coming up with a unique and engaging topic can sometimes be a daunting task. To help you get started, here are 108 dementia essay topic ideas and examples:

• The impact of dementia on individuals and their families.
• The role of genetics in the development of dementia.
• Exploring the different stages of dementia.
• The ethical considerations surrounding the care of individuals with dementia.
• The importance of early diagnosis and intervention in dementia.
• The challenges faced by caregivers of individuals with dementia.
• The impact of dementia on cognitive functions.
• Investigating the link between dementia and Alzheimer's disease.
• The role of nutrition in preventing or managing dementia.
• The social stigma associated with dementia and its effects on individuals and families.
• The potential benefits of music therapy for individuals with dementia.
• Examining the role of exercise in improving cognitive function in dementia patients.
• Exploring the impact of sleep disturbances on dementia progression.
• The influence of environmental factors on dementia risk.
• Investigating the effectiveness of non-pharmacological interventions in managing dementia symptoms.
• The economic burden of dementia on healthcare systems.
• The impact of dementia on the quality of life of individuals and their caregivers.
• The role of technology in supporting individuals with dementia.
• The potential benefits and risks of pharmacological interventions in dementia treatment.
• Examining the relationship between cardiovascular health and dementia risk.
• The impact of dementia on language and communication abilities.
• Exploring the relationship between depression and dementia.
• The importance of person-centered care in dementia management.
• The role of art therapy in improving emotional well-being in individuals with dementia.
• The potential benefits of reminiscence therapy in dementia care.
• Investigating the impact of social isolation on dementia progression.
• The role of occupational therapy in supporting individuals with dementia.
• The impact of dementia on sensory perception.
• Examining the effectiveness of cognitive stimulation therapy in improving cognitive function in individuals with dementia.
• The potential benefits of aromatherapy in managing behavioral symptoms of dementia.
• Investigating the impact of dementia on motor function and mobility.
• The role of spirituality in supporting individuals with dementia.
• The influence of cultural factors on dementia care.
• The impact of dementia on decision-making abilities.
• Exploring the relationship between diabetes and dementia.
• The potential benefits of pet therapy for individuals with dementia.
• Investigating the impact of traumatic brain injury on dementia risk.
• The role of neuroimaging in the early detection of dementia.
• The impact of dementia on sleep patterns and circadian rhythms.
• Examining the relationship between hearing loss and dementia.
• The potential benefits of mindfulness-based interventions in dementia care.
• Investigating the impact of dementia on social relationships and interactions.
• The role of respite care in supporting caregivers of individuals with dementia.
• The impact of dementia on executive functions and problem-solving abilities.
• Exploring the relationship between dementia and visual perception.
• The potential benefits of horticulture therapy in dementia care.
• Investigating the impact of dementia on emotional regulation.
• The role of nutrition in preventing or delaying dementia onset.
• The impact of dementia on the sense of self and identity.
• Examining the relationship between inflammation and dementia.
• The potential benefits of dance therapy for individuals with dementia.
• Investigating the impact of dementia on the sense of smell.
• The role of mindfulness meditation in reducing caregiver stress in dementia.
• The impact of dementia on personality and behavior.
• Exploring the relationship between traumatic childhood experiences and dementia risk.
• The potential benefits of light therapy in managing sleep disturbances in individuals with dementia.
• Investigating the impact of dementia on the ability to recognize faces.
• The role of laughter therapy in improving emotional well-being in individuals with dementia.
• The impact of dementia on the ability to perform daily living activities.
• Examining the relationship between dementia and social inequality.
• The potential benefits of virtual reality interventions in dementia care.
• Investigating the impact of dementia on the ability to navigate and orient in space.
• The role of cognitive rehabilitation in improving cognitive function in individuals with dementia.
• The impact of dementia on the ability to perceive and interpret emotions.
• Exploring the relationship between dementia and substance abuse.
• The potential benefits of animal-assisted therapy in dementia care.
• Investigating the impact of dementia on the ability to recognize objects and symbols.
• The role of humor therapy in improving emotional well-being in individuals with dementia.
• The impact of dementia on the ability to plan and execute complex tasks.
• Examining the relationship between dementia and post-traumatic stress disorder.
• The potential benefits of drama therapy for individuals with dementia.
• Investigating the impact of dementia on the ability to understand and produce language.
• The role of mindfulness-based stress reduction in supporting caregivers of individuals with dementia.
• The impact of dementia on the ability to learn and remember new information.
• Exploring the relationship between dementia and anxiety disorders.
• The potential benefits of creative writing therapy in dementia care.
• Investigating the impact of dementia on the ability to reason and make logical judgments.
• The role of cognitive-behavioral therapy in managing behavioral symptoms of dementia.
• The impact of dementia on the ability to recognize and interpret music.
• Examining the relationship between dementia and personality disorders.
• The potential benefits of art therapy for individuals with dementia.
• Investigating the impact of dementia on the ability to process and understand visual information.
• The role of mindfulness-based cognitive therapy in improving emotional well-being in individuals with dementia.
• The impact of dementia on the ability to recognize and interpret non-verbal cues.
• Exploring the relationship between dementia and sleep disorders.
• The potential benefits of poetry therapy in dementia care.
• Investigating the impact of dementia on the ability to problem-solve and make decisions.
• The role of cognitive training in improving cognitive function in individuals with dementia.
• The impact of dementia on the ability to recognize and interpret facial expressions.
• Examining the relationship between dementia and obsessive-compulsive disorder.
• The potential benefits of dance/movement therapy for individuals with dementia.
• Investigating the impact of dementia on the ability to process and understand auditory information.
• The role of acceptance and commitment therapy in improving emotional well-being in individuals with dementia.
• The impact of dementia on the ability to recognize and interpret body language.
• Exploring the relationship between dementia and eating disorders.
• The potential benefits of storytelling therapy in dementia care.
• Investigating the impact of dementia on the ability to focus and sustain attention.
• The role of cognitive reserve in delaying cognitive decline in individuals with dementia.
• The impact of dementia on the ability to recognize and understand emotions in others.
• Examining the relationship between dementia and bipolar disorder.
• The potential benefits of gardening therapy for individuals with dementia.
• Investigating the impact of dementia on the ability to inhibit impulsive behaviors.
• The role of social engagement in promoting cognitive health in individuals with dementia.
• The impact of dementia on the ability to recognize and interpret humor.
• Exploring the relationship between dementia and schizophrenia.
• The potential benefits of pet therapy for individuals with advanced dementia.
• Investigating the impact of dementia on the ability to switch between tasks and mental states.
• The role of cognitive enhancers in improving cognitive function in individuals with dementia.

Remember, these topics are just a starting point, and you can modify or combine them to suit your interests and research goals. Whether you choose to explore the biological, psychological, social, or environmental aspects of dementia, writing an essay on this topic can contribute to the understanding and improvement of dementia care and support.

Want to research companies faster?

Instantly access industry insights

Let PitchGrade do this for me

Leverage powerful AI research capabilities

We will create your text and designs for you. Sit back and relax while we do the work.

Explore More Content

• Privacy Policy
• Terms of Service

© 2024 Pitchgrade

Essay on Alzheimer’s Disease

Alzheimer’s disease (AD) is the renowned dementia’s cause worldwide and is an upsurging global health concern that is problematic at the individual level and the society. Soria Lopez, Gonzalez & Leger (2019) argue that Alzheimer’s is characterized by a decline in cognitive functions which is associated with neuropathy and age of the individual. Being the prominent form of neurodegenerative dementia, AD is linked to the disease burden amongst the minority populations in the United States. Since the disease is a considerable burden, several reviews have been undertaken to understand the disease’s epidemiology, genetics, and pathogenesis to inform new therapeutic strategies to support the transition from treatment to prevention. Thus, it is essential to monitor the symptoms of dementia, especially in the older population since they are the most high-risk population.

The initial stages of Alzheimer’s are often characterized by the inability to conceal and store new memories. In these typical fundamental signs, the individuals’ daily lives are often disrupted since difficulty recalling recent events becomes familiar, and they often misplace their items. Subsequently, behavioral and cognitive changes occur as the disease progresses to the later stages. AD patients experience synaptic loss and synaptic reduction, and even neurodegeneration due to changes in amyloid plaques. Patients are also subjected to metabolic, vascular, and inflammatory changes alongside the common comorbid pathologies such as anxiety and depression. Generally, through the seven known stages of Alzheimer’s, the signs and symptoms progress from normal outward behavior to a very severe decline.

Alzheimer’s disease is an incurable condition since it is a progressive and irreversible cause corresponding to dementia worldwide. Although its pathophysiology is not fully understood, the condition is surrounded by neurotoxic events triggered by cytoskeletal abnormalities and beta-amyloid cascade. The determination that beta-amyloid peptide is chiefly responsible for the condition has given rise to treatment goals to inhibit amyloid-beta production. Among the interventions to address the amyloid, plagues are anti-amyloid immunotherapy and activation of enzymes that degrade amyloid plaques. Active immunotherapy enhances amyloid clearance which significantly reduces the amyloid load in AD.Similarly, proteases such as neprilysin, plasmin, and endothelin degrade aggregates and amyloid plaques (Pinheiro & Faustino, 2019).In this concern, the results are that protein levels of the enzymes that contribute to the formation of amyloid-beta in AD decrease. When these therapeutic strategies are observed, the patients’ cases of neurotoxicity and neurodegeneration slow down.

AD is a neurodegenerative disease implying the difficulty to find a cure due to diagnosis difficulty and the drug struggle to get into the brain. According to Yiannopoulou, Anastasiou, Zachariou & Pelidou (2019), there are at least 200 failed Alzheimer’s trials which is a reflection that researchers are decades away from finding a cure for this dreaded disease. The common causes surrounding the cure finding difficulty include the lack of knowledge on the cause of the disease, and the lead times for new therapies are often longer than predicted. It is believed that Alzheimer’s caused by abnormal proteins amyloid and Tau build-up; thus, if this were true, there would have been positive clinical trials on removing these proteins. Secondly, the extended period taken by the FDA to approve the drug is quite inconvenient since it alters the drug development cycle. Despite not finding the cure in due time, medical practitioners are doing better in designing and suggesting remedies and therapies to treat the symptoms. The reasons surrounding the cause of the disease and drug development prove that finding a cure would continue to be a tedious process.

The struggle to find a cure is ongoing, this means that thorough research is still done, and there is a need for financial support to investigate and learn more about the disease. Currently,AD symptoms are alleviated using drug and non-drug treatments which are meant to significantly reduce the disease progression.In this concern, the caregivers are presented with the available options to help the individuals improve their quality of life. I would highly support that the funding for research to find a cure, investigate and learn about the disease should continue despite the numerous fails since if that is not done, AD will be pronounced an epidemic in a few years. Besides, funding would enable the researchers to work faster than in the past years while advancing the existing knowledge to explore ways to reduce AD risks, uncover biomarkers for treatment, and develop favorable treatments. Research funding on Alzheimer’s will be an added advantage if placed at the same rate as HIV/AIDS and cancer.

As per the many studies conducted, the changes in the brain occur before Alzheimer’s symptoms start to show. While there are no defined measures and therapies to prevent or delay the conditions, researchers have deployed therapeutic strategies to prevent or delay the disease in some people. The interventions are encouraging but inconclusive but are efficient in stimulating the mind while averting the risks of neurological disease. According to Petsko (n.d), the cases of neurological disorders will be an epidemic in the next 50 years. Precisely, epidemiological evidence outlines that lifestyle interventions and mechanisms help in delaying and preventing AD.Ko& Chye (2020), the most applicable and possibly the best lifestyle interventions are education and social engagement since they have significant effects. Alzheimer’s is incurable, but initiating and applying these interventions becomes a game-changer.

AD prominently causes dementia counted as one of the causes of death worldwide. The disease destroys an individual’s quality of life due to the known cognitive impairments and the inability to perform daily activities as usual. The inability to encode new memories and misplacing items describe the initial signs of AD. Research is still ongoing since no cure has been found, but therapeutic remedies are applied to the patient to slow the progression. People at risk of contracting the disease are advised to participate in mind-simulating activities and physical exercises. Notably, the individuals would experience a quality life provided they adhere to the suggested therapeutic remedies.

Ko, Y., & Chye, S. M. (2020). Lifestyle intervention to prevent Alzheimer’s disease.  Reviews in the Neurosciences ,  31 (8), 817-824. Doi: 10.1515/revneuro-2020-0072

Petsko, G. (n.d.). The coming neurological epidemic – Gregory Petsko. Retrieved from https://ed.ted.com/lessons/the-coming-neurological-epidemic-gregory-petsko#watch

Pinheiro, L., & Faustino, C. (2019). Therapeutic strategies targeting amyloid-β in Alzheimer’s disease.  Current Alzheimer Research ,  16 (5), 418-452. Doi: 10.2174/1567205016666190321163438

Soria Lopez, J. A., Gonzalez, H. M., & Leger, G. C. (2019). Chapter 13 – Alzheimer’s disease.  Handbook of Clinical Neurology ,  167 (3), 231-255. doi:10.1016/B978-0-12-804766-8.00013-3

Yiannopoulou, K. G., Anastasiou, A. I., Zachariou, V., & Pelidou, S. (2019). Reasons for failed trials of disease-modifying treatments for Alzheimer’s disease and their contribution in recent research. doi:10.20944/preprints201909.0270.v1

Cite This Work

To export a reference to this article please select a referencing style below:

Related Essays

Prolonged exposure therapy (pe), double pendulum design project, the history and process of health policymaking in the u.s., evidence-based practices on blood transfusion reaction procedures, out-of-class exploration: exploring laguna coast wilderness park, importance of sports, popular essay topics.

• American Dream
• Artificial Intelligence
• Black Lives Matter
• Bullying Essay
• Career Goals Essay
• Causes of the Civil War
• Child Abusing
• Civil Rights Movement
• Community Service
• Cultural Identity
• Cyber Bullying
• Death Penalty
• Depression Essay
• Domestic Violence
• Freedom of Speech
• Global Warming
• Gun Control
• Human Trafficking
• I Believe Essay
• Immigration
• Importance of Education
• Israel and Palestine Conflict
• Leadership Essay
• Legalizing Marijuanas
• Mental Health
• National Honor Society
• Police Brutality
• Pollution Essay
• Racism Essay
• Romeo and Juliet
• Same Sex Marriages
• Social Media
• The Great Gatsby
• The Yellow Wallpaper
• Time Management
• To Kill a Mockingbird
• Violent Video Games
• What Makes You Unique
• Why I Want to Be a Nurse
• Send us an e-mail

An official website of the United States government

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

• Publications
• Account settings

Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now .

• Advanced Search
• Journal List

Comprehensive Review on Alzheimer’s Disease: Causes and Treatment

Alzheimer’s disease (AD) is a disorder that causes degeneration of the cells in the brain and it is the main cause of dementia, which is characterized by a decline in thinking and independence in personal daily activities. AD is considered a multifactorial disease: two main hypotheses were proposed as a cause for AD, cholinergic and amyloid hypotheses. Additionally, several risk factors such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors play a role in the disease. Currently, there are only two classes of approved drugs to treat AD, including inhibitors to cholinesterase enzyme and antagonists to N -methyl d -aspartate (NMDA), which are effective only in treating the symptoms of AD, but do not cure or prevent the disease. Nowadays, the research is focusing on understanding AD pathology by targeting several mechanisms, such as abnormal tau protein metabolism, β-amyloid, inflammatory response, and cholinergic and free radical damage, aiming to develop successful treatments that are capable of stopping or modifying the course of AD. This review discusses currently available drugs and future theories for the development of new therapies for AD, such as disease-modifying therapeutics (DMT), chaperones, and natural compounds.

1. Introduction

Alzheimer’s disease (AD) (named after the German psychiatric Alois Alzheimer) is the most common type of dementia and can be defined as a slowly progressive neurodegenerative disease characterized by neuritic plaques and neurofibrillary tangles ( Figure 1 ) as a result of amyloid-beta peptide’s (Aβ) accumulation in the most affected area of the brain, the medial temporal lobe and neocortical structures [ 1 ]. Alois Alzheimer noticed a presence of amyloid plaques and a massive loss of neurons while examining the brain of his first patient that suffered from memory loss and change of personality before dying and described the condition as a serious disease of the cerebral cortex. Emil Kraepelin named this medical condition Alzheimer’s disease for the first time in his 8th edition psychiatry handbook [ 2 , 3 ]. Progressive loss of cognitive functions can be caused by cerebral disorder like Alzheimer’s disease (AD) or other factors such as intoxications, infections, abnormality in the pulmonary and circulatory systems, which causes a reduction in the oxygen supply to the brain, nutritional deficiency, vitamin B12 deficiency, tumors, and others [ 4 , 5 ].

The physiological structure of the brain and neurons in ( a ) healthy brain and ( b ) Alzheimer’s disease (AD) brain.

At present, there are around 50 million AD patients worldwide and this number is projected to double every 5 years and will increase to reach 152 million by 2050. AD burden affects individuals, their families, and the economy, with estimated global costs of US$1 trillion annually. At present, there is no cure for Alzheimer’s disease, although there are available treatments that just improve the symptoms [ 6 , 7 ]. The purpose of this review is to give a brief description about AD diagnosis, pathology, causes, and current treatments, and to highlight the recent development of compounds that could prevent or treat AD by targeting several pathogenic mechanisms, such as Aβ and tau aggregation, and misfolding, inflammation, oxidative damage, and others.

2. Alzheimer’s Disease Diagnostic Criteria

A patient suspected to have AD should undergo several tests, including neurological examination, magnetic resonance imaging (MRI) for neurons, laboratory examinations such as vitamin B12, and other tests besides the medical and family history of the patients [ 8 ]. Vitamin (vit.) B12 deficiency has been long known for its association with neurologic problems and increasing risks of AD, according to some studies. A special marker of vit. B12 deficiency is elevated homocysteine levels, which can cause brain damage by oxidative stress, increasing calcium influx and apoptosis. Diagnoses of vit. B12 deficiency can be done by measuring serum vit. B12 level alongside complete blood count and serum homocysteine levels tests [ 9 , 10 ].

In 1984, The National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer’s Disease and Related Disorders Association (ADRDA) formed a work group (NINCDS-ADRDA) to establish a clinical diagnostic’s criteria for Alzheimer’s disease. This criteria includes: (1) probable Alzheimer’s disease, which can be diagnosed by dementia that is confirmed by neuropsychological tests, progressive memory loss, impaired daily-life activity, and other symptoms like aphasia (impairment of a language), apraxia (a motor skills disorder), and agnosia (a loss of perception). All of these symptoms can start from age 40–90, with the absence of any systemic or brain diseases, (2) possible Alzheimer’s disease can be applied in the absence of neurologic, psychiatric disorders, and the presence of another illness like systemic or brain disorder, but they are not the primary cause of dementia, and (3) definite Alzheimer’s disease, that is confirmed by histopathologic confirmation obtained from a biopsy or autopsy [ 11 , 12 ].

In 2011, The National Institute on Aging—Alzheimer’s Association made several changes and updated the 1984 NINCDS-ADRDA criteria for higher specificity and sensitivity in the diagnosis of Alzheimer’s disease. The newly proposed criteria include probable and possible AD dementia for the use in clinical settings and probable or possible AD dementia with pathophysiological evidence for research purposes, in addition to clinical biomarkers. There are two categories of Alzheimer’s disease biomarkers: (a) markers of brain amyloid such as positron emission tomography (PET) and cerebrospinal fluid (CSF), and (b) markers of neuronal injury like cerebrospinal fluid tau, fluorodeoxyglucose (FDG) for metabolic activity, and magnetic resonance imaging (MRI) for atrophy measurement [ 13 , 14 , 15 ].

3. Alzheimer’s Disease’s Neuropathology

There are two types of neuropathological changes in AD which provide evidence about disease progress and symptoms and include: (1) positive lesions (due to accumulation), which are characterized by the accumulation of neurofibrillary tangles, amyloid plaques, dystrophic neurites, neuropil threads, and other deposits found in the brains of AD patients. In addition to (2) negative lesions (due to losses), that are characterized by large atrophy due to a neural, neuropil, and synaptic loss. Besides, other factors can cause neurodegeneration such as neuroinflammation, oxidative stress, and injury of cholinergic neurons [ 16 , 17 , 18 ].

3.1. Senile Plaques (SP)

The senile plaques are extracellular deposits of beta-amyloid protein (Aβ) with different morphological forms, including neuritic, diffuse, dense-cored, or classic and compact type plaques. Proteolytic cleavage enzymes such as β-secretase and γ-secretase are responsible for the biosynthesis of Aβ deposits from the transmembrane amyloid precursor protein (APP) [ 19 , 20 , 21 ]. These enzymes cleave APP into several amino acid fragments: 43, 45, 46, 48, 49, and 51 amino acids, which reach the final forms Aβ40 and Aβ42. There are several types of Aβ monomers, including large and insoluble amyloid fibrils which can accumulate to form amyloid plaques and soluble oligomers that can spread throughout the brain. Aβ plays a major role in neurotoxicity and neural function, therefore, accumulation of denser plaques in the hippocampus, amygdala, and cerebral cortex can cause stimulation of astrocytes and microglia, damage to axons, dendrites, and loss of synapses, in addition to cognitive impairments [ 21 , 22 , 23 ].

3.2. Neurofibrillary Tangles (NFTs)

NFT are abnormal filaments of the hyperphosphorylated tau protein that in some stages can be twisted around each other to form paired helical filament (PHF) and accumulate in neuralperikaryal cytoplasm, axons, and dendrites, which cause a loss of cytoskeletal microtubules and tubulin-associated proteins. The hyperphosphorylated tau protein is the major constituent of NFTs in the brains of AD patients, and its evolution can reflect NFTs morphological stages, which include: (1) pre-tangle phase, one type of NFT, where phosphorylated tau proteins are accumulated in the somatodendritic compartment without the formation of PHF, (2) mature NFTs, which are characterized by filament aggregation of tau protein with the displacement of the nucleus to the periphery part of the soma, and (3) the extracellular tangles, or the ghost NFTs stage, that results from a neuronal loss due to large amounts of filamentous tau protein with partial resistance to proteolysis [ 24 , 25 ].

3.3. Synaptic Loss

A synaptic damage in the neocortex and limbic system causes memory impairment and generally is observed at the early stages of AD. Synaptic loss mechanisms involve defects in axonal transport, mitochondrial damage, oxidative stress, and other processes that can contribute to small fractions, like the accumulation of Aβ and tau at the synaptic sites. These processes eventually lead to a loss of dendritic spines, pre-synaptic terminals, and axonal dystrophy [ 26 ]. Synaptic proteins serve as biomarkers for the detection of synapses loss, and severity, such as neurogranin, a postsynaptic neuronal protein, visinin-like protein-1 (VILIP-1), and synaptotagmin-1 [ 27 , 28 ].

4. The Stages of Alzheimer’s Disease

The clinical phases of Alzheimer’s disease can be classified into (1) pre-clinical or the pre-symptomatic stage, which can last for several years or more. This stage is characterized by mild memory loss and early pathological changes in cortex and hippocampus, with no functional impairment in the daily activities and absence of clinical signs and symptoms of AD [ 1 , 29 , 30 ]. (2) The mild or early stage of AD, where several symptoms start to appear in patients, such as a trouble in the daily life of the patient with a loss of concentration and memory, disorientation of place and time, a change in the mood, and a development of depression [ 30 , 31 ]. (3) Moderate AD stage, in which the disease spreads to cerebral cortex areas that results in an increased memory loss with trouble recognizing family and friends, a loss of impulse control, and difficulty in reading, writing, and speaking [ 30 ]. (4) Severe AD or late-stage, which involves the spread of the disease to the entire cortex area with a severe accumulation of neuritic plaques and neurofibrillary tangles, resulting in a progressive functional and cognitive impairment where the patients cannot recognize their family at all and may become bedridden with difficulties in swallowing and urination, and eventually leading to the patient’s death due to these complications [ 1 , 32 ].

5. Causes and Risk Factors of Alzheimer’s Disease

AD has been considered a multifactorial disease associated with several risk factors ( Figure 2 ) such as increasing age, genetic factors, head injuries, vascular diseases, infections, and environmental factors (heavy metals, trace metals, and others). The underlying cause of pathological changes in Alzheimer’s disease (Aβ, NFTs, and synaptic loss) is still unknown. Several hypotheses were proposed as a cause for AD but two of them are believed to be the main cause: some believe that an impairment in the cholinergic function is a critical risk factor for AD, while others suggest that alteration in amyloid β-protein production and processing is the main initiating factor. However, at present, there is no accepted theory for explaining the AD pathogenesis [ 33 , 34 ].

The risk factors for Alzheimer’s disease.

5.1. Alzheimer’s Disease Hypotheses

5.1.1. cholinergic hypothesis.

In the 1970s, neocortical and presynaptic cholinergic deficits were reported to be related to the enzyme choline acetyltransferase (ChAT), which is responsible for the synthesis of acetylcholine (ACh). Due to the essential role of ACh in cognitive function, a cholinergic hypothesis of AD was proposed. ACh is synthesized in the cytoplasm of cholinergic neurons from choline and acetyl-coenzyme A by the ChAT enzyme and transported to the synaptic vesicles by vesicular acetylcholine transporter (VAChT) ( Figure 3 ). In the brain, ACh is involved in several physiological processes such as memory, attention, sensory information, learning, and other critical functions. Degeneration of the cholinergic neurons was found to take place in AD and to cause alternation in cognitive function and memory loss. Β -amyloid is believed to affect cholinergic neurotransmission and to cause a reduction in the choline uptake and a release of ACh. Studies demonstrated that cholinergic synaptic loss and amyloid fibril formation are related to Aβ oligomers’ neurotoxicity and to interactions between AChE and Aβ peptide. Additional factors also contribute to the progression of AD, such as a reduction in nicotinic and muscarinic (M2) Ach receptors, located on presynaptic cholinergic terminals, and the deficit in excitatory amino acid (EAA) neurotransmission, where glutamate concentration and D-aspartate uptake are significantly reduced in many cortical areas in AD brains. This is in addition to the use of cholinergic receptor antagonists such as scopolamine, which was found to induce amnesia. This effect can be reversed by using compounds that activate acetylcholine formation [ 35 , 36 , 37 ].

The pathway for the synthesis and transportation of acetylcholine between presynaptic and postsynaptic nerve terminals.

As a result, the cholinergic hypothesis is based on three concepts: reduced presynaptic cholinergic markers in the cerebral cortex, severe neurodegeneration of nucleus basalis of Meynert (NBM) in the basal forebrain, which is the source of cortical cholinergic innervation, and the role of cholinergic antagonists in memory decline compared to the agonists, which have the opposite effect [ 38 ].

5.1.2. Amyloid Hypothesis

For decades, it was recognized that abnormal deposition of β-sheets in the central nervous system has a strong correlation with dementia, which led to the concept of the amyloid hypothesis. However, it was found that the amyloid plaques (AP) also deposit in normal healthy brains with aging, which raised the question of whether AP deposition is responsible for AD onset or not? Therefore, in the recent years, alternative hypotheses were proposed for the non-inherited form of AD (NIAD), but at present, the amyloid hypothesis remains the most accepted pathological mechanism for inherited AD (IAD). The amyloid hypothesis suggests that the degradation of Aβ, derived from APP by β- and γ-secretase, is decreased by age or pathological conditions, which leads to the accumulation of Aβ peptides (Aβ40 and Aβ42). Increasing the ratio of Aβ42/Aβ40 induces Aβ amyloid fibril formation, resulting in neurotoxicity and tau pathology induction, and consequently, leading to neuronal cell death and neurodegeneration. AD risk factors and mutations of several genes like APP, PSEN1, and PSEN2 were found to affect Aβ catabolism and anabolism, which rapidly cause an accumulation of Aβ and fast progression of neurodegeneration [ 39 , 40 , 41 ].

5.2. Alzheimer’s Disease Risk Factors

5.2.1. aging.

The most important risk factor in AD is aging. Younger individuals rarely have this disease, and most AD cases have a late onset that starts after 65 years of age [ 42 ]. Aging is a complex and irreversible process that occurs through multiple organs and cell systems with a reduction in the brain volume and weight, a loss of synapses, and ventricles’ enlargement in specific areas accompanied by SP deposition and NFT. Moreover, several conditions might emerge during aging such as glucose hypometabolism, cholesterol dyshomeostasis, mitochondria dysfunction, depression, and cognitive decline. These changes also appear in normal aging, which makes it difficult to distinguish the cases in early AD [ 43 , 44 ]. AD can be divided based on age of onset into early-onset AD (EOAD), the rare form with around 1–6% of cases, in which most of them are familial AD characterized by having more than one member in more than one generation with AD, and ranges from 30–60 or 65 years. The second type is the late-onset AD (LOAD), which is more common with age of onset above 65 years. Both types may occur in people who have a family with a positive history of AD and families with a late-onset disease [ 45 ].

5.2.2. Genetics

Genetic factors were discovered over the years and were found to play a major role in the development of AD. 70% of the AD cases were related to genetic factors: most cases of EOAD are inherited in an autosomal dominant pattern and mutations in the dominant genes such as Amyloid precursor protein (APP) , Presenilin-1 (PSEN-1), Presenilin-2 (PSEN-2) , and apolipoprotein E (ApoE) are associated with AD [ 46 , 47 ].

Herein, we discuss the strong genetic risk factors in AD.

• Amyloid Precursor Protein (APP)

APP is a type I transmembrane protein cleaved by α-, β-, and γ-secretase to release Aβ and other proteins and is encoded by the APP gene on chromosome 21. Thirty mutations have been found in the APP gene in which twenty-five of them are related to AD and cause an accumulation of Aβ with elevated amounts. Meanwhile, there is one protective mutation, A673T, which protects against AD by decreasing Aβ, Aβ40, and Aβ42 secretion [ 48 , 49 ]. All mutations surround the secretase cleavage site, for example, the KM670/671NL mutation in mouse models has shown an increasing level of amyloid plaques in the hippocampus and cortex with no NFTs. A673V, D678H, D678N, E682K, and K687N mutations have shown cortical atrophy, whereas E682K has shown hippocampal atrophy. Neuropathological reports for the A673V mutation demonstrated a presence of NFTs and Aβ, activation of microglia and astrocytes, and neuronal loss, compared to the rest of the mentioned mutations, which show no change in the intracellular Aβ according to neuropathological reports [ 48 , 50 ]. Other mutations such as T714I, V715A, V715M, V717I, V717L, L723P, K724N, and I716V affect the γ-secretase cleavage site and cause an increase in the Aβ42/Aβ40 ratio, while E693G, E693K, D694N, and A692G mutations affect the α-secretase cleavage site and cause polymorphic aggregates with the ability to disrupt bilayer integrity. Also, the E693delta is a deletion mutation that enhances the formation of synaptotoxic Aβ [ 51 , 52 ].

• Presenilin-1 (PSEN-1) and Presenilin-2 (PSEN-2)

PSEN1 and PSEN2 genes are also the autosomal dominant form of EOAD located on chromosomes 14 and 1, respectively. PSEN-2 and PSEN-1 are homologous, with 67% similarity, with a difference in the N -terminus and the hydrophilic region. Mutation in PSEN1 gene is more common, with more than 200 mutations, while a rare form with less than 40 mutations was identified in the PSEN2 gene [ 53 , 54 ].

PSEN1 is a core protein that activates the γ-secretase complex and plays an important role in the production of Aβ from APP. Knockout studies of PSEN1 showed synaptic dysfunction and memory impairment in mice, which indicate its essential role in maintaining memory and neurons [ 51 ]. PSEN1 mutations are simple ones which include single amino acid substitution, and severe mutation can result from the substitutions of two amino acids [ 55 ]. Mutations in the PSEN1 gene increase the ratio of Aβ42/Aβ40 by decreasing Aβ40 levels. The results obtained by Sun et al. study demonstrated that C410Y or L435F mutations in PSEN1 knock-in mice increased the Aβ42/Aβ40 ratio due to a greater reduction in Aβ40 [ 56 ].

In contrast, PSEN-2 mutations are rare and play a minor role in Aβ production. Any mutation in PSEN-2 might have a severe effect on the Aβ 42/40 ratio, causing familial AD in the presence of normal PSEN-1 alleles. Some of the PSEN-2 mutations cause a significant increase in γ-secretase activity with an elevation in the Aβ-42 and Aβ 42/40 ratio level, such as N141I, T122P, M239V, and M239I, while others are rare polymorphisms and have no effect on Aβ-42, -40, and Aβ 42/40 ratio levels and are not considered as pathogenic mutations [ 53 , 57 ].

• Apolipoprotein E (ApoE)

ApoE protein is a glycoprotein expressed highly in the liver and brain astrocytes and some microglia and serves as a receptor-mediated endocytosis ligand for lipoprotein particles like cholesterol, which is essential for myelin production and normal brain function. The ApoE gene located on chromosome 19 has three isoforms, ApoE2, ApoE3, and ApoE4, due to single-nucleotide polymorphisms (SNPs) which cause changes in the coding sequence. The ApoEε4 allele is a strong risk factor for both EOAD and LOAD compared to ApoEε2 and ApoEε3 alleles that are associated with a lower risk and protective effect, respectively [ 58 ]. ApoEε4 plays an important role in Aβ deposition as a senile plaque and causes cerebral amyloid angiopathy (CAA), which is known as a marker for AD [ 59 ]. ApoEε4 was also shown to be associated with vascular damage in the brain, which leads to AD pathogenesis [ 60 ].

• ATP Binding Cassette Transporter A1 (ABCA1)

Adenosine triphosphate (ATP)-binding cassette transporter A1 (ABCA1) is part of a large ABC transporters family that regulate cholesterol efflux in the circulation, like apolipoproteins-AI (ApoAI), and into the brain, like ApoE. In addition, ABCA1 maintains the stability of ApoE lipidation and serves as a mediator for high-density lipoprotein (HDL) generation, which reflects its role in atherosclerosis and cardiovascular diseases. Studies on the AD mice model showed that ABCA1 deficiency increases amyloid plaques and eliminates the lipidation of ApoE [ 61 ]. In humans, a mutation in ABCA1 results in Tangier disease, which is characterized by low levels of high-density lipoprotein (HDL) and ApoAI in plasma, accumulation of cholesterol in tissues, and AD pathogenesis [ 62 ].

• Clusterin Gene (CLU) and Bridging Integrator 1 ( BIN1 )

In contrast to PSEN1 , PSEN2 , and APP mutations, which result in familial or EOAD, clusterin ( CLU) and Bridging Integrator 1 ( BIN1 ) genes are novel risk factors for LOAD. In 2009, Genome-Wide Association Studies (GWAS) identified the CLU gene located on chromosome 8, which is upregulated in the cortex and hippocampus of AD brains, in addition to AD cerebrospinal fluid (CSF) and plasma, which make the CLU a promising biomarker for AD. The CLU may play a protective role by interacting with Aβ and promoting its clearance, or a neurotoxic role by reducing Aβ clearance. The Aβ ratio values determine whether the CLU role is neuroprotective or neurotoxic [ 63 ].

BIN1 is a Bin-Amphiphysin-Rvs (BAR) adaptor protein that is involved in the production of membrane curvature and other endocytosis cellular functions. BIN1 has several isoforms: some are found in the brain, where they interact with different proteins such as clathrin, synaptojanin, and amphiphysin 1, and others in which they regulate synaptic vesicle endocytosis. Recently, BIN1 was recognized as the second most important risk factor for LOAD after ApoE, where it plays a role in Aβ production and as a tau and NFT pathology modulator [ 64 , 65 ].

• Evolutionarily Conserved Signaling Intermediate in Toll pathway (ECSIT)

A significant accumulation of Aβ in AD brains increases protein oxidation, which reflects the critical role of mitochondria in Aβ cytotoxicity and AD pathogenesis. Evolutionarily conserved signaling intermediate in Toll pathway (ECSIT) gene is located on chromosome 19 and is associated with increasing the risk of AD. ECSIT encodes the adapting protein that functions as a cytoplasmic and signaling protein and is responsible for stabilizing the mitochondrial respiratory complex. Moreover, the adaptor protein is involved in the activation of nuclear factor (NF)-κB, interferon regulatory factors (IRFs), and activating protein-1. Also, it is involved in coupling immune toll-like receptor (TLR), homeostatic bone morphogenetic pathway (BMP), and transforming growth factor-beta (TGF-b) pathways [ 66 , 67 ].

ECSIT interacts with mitochondrial proteins such as Lon protease homolog (LONP1) and glutaryl-CoA dehydrogenase (GCDH), which are involved in intra-mitochondrial proteolysis and redox signaling respectively, followed by interactions with AD seed nitric oxide synthase (NOS3). Moreover, studies have shown certain interactions of ECSIT with the AD genes ApoE , PSEN-1 , and PSEN-2 . These interactions support the role of ECSIT as a molecular link in oxidative stress, inflammation, and mitochondrial dysfunction in AD [ 66 , 68 ].

• Estrogen Receptor Gene (ESR)

AD affects both women and men, but nearly two-thirds of AD cases are women. Several studies have shown that women with AD experience worse mental deterioration than men. Additionally, on the genetic level, some genes’ variation, like the ApoE4 allele, significantly increases AD risk in women compared to men. Other studies documented that AD risk in women is associated with the loss of ovarian hormones during menopause due to the fact that estrogen regulates several activities in the brain, such as neurotransmission, neural development, survival, protection against oxidative stress, reduction of Aβ peptide levels, and attenuation of tau hyperphosphorylation. The estrogen activity is mediated through estrogen receptors (ERs) (intracellular, transmembrane, and membrane-bound ERs). The two major subtypes of these receptors are ERα and Erβ, which are encoded by two distinct genes and are located on chromosome 6 and 14, respectively. ERα receptor is found in the hypothalamus and amygdala, whereas ERβ receptors are in the hippocampus and cortex. Single nucleotide polymorphisms (SNPs) in ERβ and ERα genes may affect exogenous estrogen in older women and influence cognitive aging. PvuII (rs9340799) and Xbal (rs223493) are examples of SNPs found in ERα and are associated with AD and cognitive impairment. Also, several SNPs in ERβ have been proven to increase the risk of AD in women [ 69 , 70 , 71 , 72 ].

• Other Genes

Other genes’ polymorphism associated with increasing the risk of AD include vitamin D receptor (VDR) gene polymorphism, which affects the affinity of vitamin D to its receptor and may cause neurodegenerative diseases and neuronal damage [ 73 ]. Moreover, epigenetic factors like DNA methylation, histone, and chromatin modifications were demonstrated to be involved in AD [ 33 , 74 ].

5.2.3. Environmental Factors

Aging and genetic risk factors cannot explain all cases of AD. Environmental risk factors including air pollution, diet, metals, infections, and many others may induce oxidative stress and inflammation and increase the risk for developing AD. Herein, we report the most important environmental factors and their relationships with AD [ 75 , 76 ].

• Air Pollution

The air pollution is characterized by modifying the nature of the atmosphere through the introduction of chemical, physical, or biological pollutants. It is associated with respiratory and cardiovascular diseases and recently, its association with AD was documented. Six air pollutants have been defined by National Ambient Air Quality Standards (NAAQSs) in the USA as a threat to human health, including ozone (O 3 ), nitrogen oxides (NO x ), carbon monoxide (CO), particulate matter (PM), sulfur dioxide (SO 2 ), and lead. Studies on animals and cellular models have shown that an exposure to high levels of air pollution can result in a damage to the olfactory mucosa and bulb, in addition to the frontal cortex region, similar to that observed in AD. In individuals exposed to air pollutants, there is a link between oxidative stress, neuroinflammation, and neurodegeneration, with the presence of hyper-phosphorylated tau and Aβ plaques in the frontal cortex. The air pollution can cause an increase in Aβ 42 formation, accumulation, and impaired cognitive function [ 77 , 78 ].

In recent years, the number of studies on the role of nutrition in AD have been increased. Several dietary supplements such as antioxidants, vitamins, polyphenols, and fish were reported to decrease the risk of AD, whereas saturated fatty acids and high-calorie intake were associated with increasing the risk of AD [ 79 ]. The food processing causes degradation of heat-sensitive micronutrients (e.g., vitamin C and folates), loss of large amounts of water, and formation of toxic secondary products (advanced glycation end products, AGEs) from non-enzymatic glycation of free amino groups in proteins, lipids, and nucleic acids. The toxic effect of AGEs is referred to as their ability to induce oxidative stress and inflammation by modifying the structure and function of the cell surface receptors and body proteins. Different studies demonstrated that elevated AGEs serum level is associated with cognitive decline and progression of AD. The AGE receptor (RAGE) is located in different places within the body, including microglia and astrocytes, and was established to be overexpressed in the brain of AD patients and serve as a transporter and a cell surface receptor for Aβ [ 80 ]. Malnutrition is another risk factor for AD. Deficiency in nutrients such as folate, vitamin B12, and vitamin D may cause a decrease in cognitive function, in addition to the fact that patients with AD suffer from problems associated with eating and swallowing, which may increase the risk of malnutrition [ 81 ].

Metals are found in nature and biological systems and can be divided into bio-metals that have a physiological function in living organisms (e.g., copper, zinc, and iron), and toxicological metals which do not possess any biological function (e.g., aluminum and lead) [ 82 ]. Aluminum is used significantly in the industries such as processed foods, cosmetics, medical preparations, medicines, and others. In the body, aluminum is bound to plasma transferrin and to citrate molecules that can mediate the transfer of aluminum to the brain. Studies demonstrated that Al accumulates in the cortex, hippocampus, and cerebellum areas, where it interacts with proteins and causes misfolding, aggregation, and phosphorylation of highly phosphorylated proteins like tau protein, characteristic of AD [ 83 ]. Lead competes with the binding site of bio-metals like calcium and can cross the blood–brain barrier (BBB) rapidly, where it can modify neural differentiation and synaptogenesis and cause severe damage. Studies revealed that an acute exposure to lead was associated with AD and caused an increase of β-secretase expression and Aβ accumulation. Cadmium is a carcinogenic water-soluble metal that can cross the BBB and cause neurological diseases like AD. Results have demonstrated that Cadmium ions are involved in the aggregation of Aβ plaques and the self-aggregation of tau in the AD brain. The data accumulated on metals support the notion that they are among the risk factors involved in the development of AD [ 84 ].

Chronic infections to the central nervous system (CNS) can cause an accumulation of Aβ plaques and NFT, therefore, they are included among the risk factors in AD. Studies by Dr. Itzhaki showed that the DNA of herpes simplex virus (HSV-1) was found in patients with ApoE-ε4 allele carriers, which explains the high risk for developing AD. HSV-1 can replicate in the brain, which can result in the activation of the inflammatory response and an increase in Aβ deposition, resulting in damage to neurons and gradual development of AD. On the other hand, the study results by Miklossy and Balin’s have revealed the role of chronic bacterial infections in AD. For example, syphilitic dementia caused by spirochete bacteria ( Treponema pallidum ), which are accumulated in the cerebral cortex, produced lesions similar to neurofibrillary tangles, which led to devastating neurodegenerative disorders. Besides, Chlamydia pneumonia bacterium can trigger late-onset AD by activation of astrocyte and cytotoxic microglia, disrupt calcium regulation and apoptosis, resulting in deterioration of cognitive function, and increase the risk of AD [ 85 , 86 , 87 ].

5.2.4. Medical Factors

Several risk factors are related to the development of Alzheimer’s disease. Adding to this list, older people with AD usually have medical conditions such as cardiovascular disease (CVD), obesity, diabetes, and others. All of these conditions are associated with increased risk of AD [ 88 , 89 ].

• Cardiovascular Disease (CVDs)

CVDs are recognized as an important risk factor for AD, such as the stroke that is associated with increased risk of dementia due to a neural tissue loss, which enhances degenerative effect and influences amyloid and tau pathology. Atrial fibrillation also causes embolisms which leads to stroke and a decrease in memory and cognitive functions. Moreover, heart failure affects the pumping function of the heart and results in insufficient blood supply to the body and hypo-perfusion of the brain that leads to hypoxia and neural damage. The coronary heart disease’s hypothesis indicates that atherosclerosis, peripheral artery disease, hypo-perfusion, and emboli are all related to increased risk of AD. Hypertension is associated with thickening of vessel walls and narrowing of the lumen which reduce the cerebral blood flow, and in chronic cases, it may cause cerebral edema, which all participate as risk factors for AD and CVD. The CVD is a modifiable risk factor and by focusing on its relationship with AD, a pathway to prevent and delay the disease can be obtained [ 89 , 90 ].

• Obesity and Diabetes

Obesity is a term used for too much body fat in individuals due to consuming more calories than they burn and can be calculated by using the body mass index (BMI). Increasing the body fat is associated with a decreased brain blood supply which promotes brain ischemia, memory loss, and vascular dementia. The obesity, unhealthy diet, and other factors can cause impaired glucose tolerance (IGT) or diabetes, which is characterized by hyperglycemia that affects peripheral tissues and blood vessels. Chronic hyperglycemia can induce cognitive impairment as a result of increasing amyloid-beta accumulation, oxidative stress, mitochondrial dysfunction, and neuroinflammation. Obesity is characterized by increasing pro-inflammatory cytokines secretions from adipose tissue, which stimulate macrophages and lymphocytes and eventually lead to local and systemic inflammation. This inflammation promotes insulin resistance, hyperinsulinemia, and as a consequence, hyperglycemia. Obesity is a well-known risk factor for type 2 diabetes, CVDs, and cancer, which are identified as risk factors for dementia and AD. The brain inflammation causes an increase in microglia and results in reduced synaptic plasticity and impaired neurogenesis. Microglia can affect insulin receptor substrate 1 (IRS-1) and block intracellular insulin signaling, which has an important role in neural health. Therefore, alteration in insulin action can result in Aβ accumulation and reduce the tau protein degradation associated with AD [ 91 , 92 , 93 , 94 ].

6. Treatment

Currently, Alzheimer’s disease cases worldwide are reported to be around 24 million, and in 2050, the total number of people with dementia is estimated to increase 4 times. Even though AD is a public health issue, as of now, there is only two classes of drugs approved to treat AD, including inhibitors to cholinesterase enzyme (naturally derived, synthetic and hybrid analogues) and antagonists to N -methyl d -aspartate (NMDA). Several physiological processes in AD destroy Ach-producing cells which reduce cholinergic transmission through the brain. Acetylcholinesterase inhibitors (AChEIs), which are classified as reversible, irreversible, and pseudo-reversible, act by blocking cholinesterase enzymes (AChE and butyrylcholinesterase (BChE)) from breaking down ACh, which results in increasing ACh levels in the synaptic cleft [ 95 , 96 , 97 ]. On the other hand, overactivation of NMDAR leads to increasing levels of influxed Ca 2+ , which promotes cell death and synaptic dysfunction. NMDAR antagonist prevents overactivation of NMDAR glutamate receptor and hence, Ca 2+ influx, and restores its normal activity. Despite the therapeutic effect of these two classes, they are effective only in treating the symptoms of AD, but do not cure or prevent the disease [ 98 , 99 ]. Unfortunately, only a few clinical trials on AD have been launched in the last decade and their outcome was a big failure. Several mechanisms have been proposed to understand AD pathology in order to modify its pathway and develop successful treatments, which include abnormal tau protein metabolism, β-amyloid, inflammatory response, and cholinergic and free radical damage [ 30 , 100 ]. On the other hand, most AD modifiable risk factors such as cardiovascular or lifestyle habits can be prevented without medical intervention. Studies showed that physical activity can improve the brain health and reduce AD by activating the brain vascularization, plasticity, neurogenesis, and reducing inflammation by decreasing Aβ production, which all result in improving cognitive function in older people. Moreover, the Mediterranean diet (MD), intellectual activity, and higher education all may reduce the progression of AD and memory loss and increase the brain capacity and cognitive functions. Several studies revealed that multi-domain intervention which includes lifestyle (diet, exercise, and cognitive training), depression of AD symptoms, and controlling cardiovascular risk factors, can increase or maintain cognitive function and prevent new cases of AD in older people [ 101 ]. Herein, we summarize the currently available drugs and theories for the development of new therapies for AD.

6.1. Symptomatic Treatment of AD

6.1.1. cholinesterase inhibitors.

According to the cholinergic hypothesis, AD is due to the reduction in acetylcholine (ACh) biosynthesis. Increasing cholinergic levels by inhibiting acetylcholinesterase (AChE) is considered one of the therapeutic strategies that increases cognitive and neural cell function. AChEIs are used to inhibit acetylcholine degradation in the synapses, which results in continuous accumulation of ACh and activation of cholinergic receptors. Tacrine (tetrahydroaminoacridine) ( 1, Figure 4 ) was the first FDA (Food and Drug Administration)-approved cholinesterase inhibitor drug for the treatment of AD, which acts by increasing ACh in muscarinic neurons, but it exited the market immediately after its introduction due to a high incidence of side effects like hepatotoxicity and a lack of benefits, which was observed in several trials. Later on, several AChEIs were introduced, such as donepezil ( 2 , Figure 4 ), rivastigmine ( 3 , Figure 4 ), and galantamine ( 4 , Figure 4 ), and are currently in use for the symptomatic treatment of AD [ 34 , 97 , 102 , 103 ]. Another strategy that may help in the treatment of AD is increasing choline reuptake and as a result, increasing acetylcholine synthesis at the presynaptic terminals. This can be achieved by targeting choline transporter (CHT1) which is responsible for supplying choline for the synthesis of ACh. Developing drugs that are capable of increasing CHT1 at the plasma membrane may become the future therapy of AD [ 36 ].

The chemical structures of approved drugs for symptomatic treatment of AD (tacrine 1 , donepezil 2 , rivastigmine 3 , galantamine 4 , and memantine 5 ) and disease-modifying compounds that entered clinical trials (semagacestat 6 , avagacestat 7 , tarenflurbil 8 , lanabecestat 9 , verubecestat 10 , atabecestat 11 , umibecestat 12 , methylene blue 13 , tideglusib 14 , and saracatinibin 15 ).

Donepezil ( 2 , Figure 4 ) is an indanonebenzylpiperidine derivative and a second generation of AChEIs and is considered the leading drug for AD treatment. Donepezil binds to acetylcholinesterase reversibly and inhibits acetylcholine hydrolysis, which leads to a higher concentration of ACh at the synapses. The drug is well-tolerated with mild and transient cholinergic side effects which are related to the gastrointestinal and nervous systems. It should be noted that donepezil is used to treat symptoms of AD such as improving cognition and behavior without altering the AD progression [ 104 , 105 , 106 ].

• Rivastigmine

Rivastigmine ( 3 , Figure 4 ) is a pseudo irreversible inhibitor of AChE and butyrylcholinesterase (BuChE) that acts by binding to the two active sites of AChE (anionic and estearic sites), which results in preventing ACh metabolism. BuChE is found mostly in glial cells with only 10% of AChE activity in the normal brain, whereas in the AD brain, its activity is increased to 40–90%, while ACh activity is reduced simultaneously, which suggests that BuChE action may indicate a moderate to severe dementia. Rivastigmine dissociates more slowly than AChE, which is why it is called a pseudo-irreversible, and it undergoes metabolism at the synapse by AChE and BuChE. The drug is used in mild to moderate AD cases. It improves cognitive functions and daily life activities. Oral administration of the drug is associated with adverse effects such as nausea, vomiting, dyspepsia, asthenia, anorexia, and weight loss. In many cases, these side effects are the main reason behind stopping taking the medicine, however, they can be settled down in time and consequently, the drug becomes more tolerated. Rivastigmine can be delivered by transdermal patches for controlled and continuous delivery of the drug through the skin, with enhanced tolerability and caregiver satisfaction. Also, the patches can deliver a lower dosage compared to pills, which results in reduced side effects. Most AD patients suffer from memory loss and swallowing problems which affect their compliance in administering oral drugs at regular intervals. Therefore, the use of transdermal patches is the most appropriate method for delivering the drug in AD patients [ 107 , 108 , 109 , 110 ].

• Galantamine (GAL)

Galantamine ( 4 , Figure 4 ) is considered a standard first-line drug for mild to moderate AD cases. GAL is a selective tertiary isoquinoline alkaloid with a dual mechanism of action in which it acts as a competitive inhibitor of AChE and can bind allosterically to the α-subunit of nicotinic acetylcholine receptors and activate them. GAL can improve behavioral symptoms, daily life activities, and cognitive performance with good efficacy and tolerability, similar to other AChE inhibitors. Several delivery systems were developed to improve the drug delivery to the brain: Wahba et al. attached GAL to ceria-containing hydroxyapatite particles for selective delivery of the drug to the affected regions in the brain. Misra et al. and Fornaguera et al. used solid-lipid nanoparticles and nano-emulsification approaches respectively, to carry GAL hydrobromide. The results of these studies demonstrated a promising strategy for safe delivery of the drug. Hanafy et al. developed nasal GAL hydrobromide/chitosan complex nanoparticles which showed good pharmacological efficacy, while Woo et al. utilized the patch system as a carrier for a controlled release dosage form of the drug [ 111 , 112 , 113 , 114 ].

6.1.2. N -methyl d -aspartate (NMDA) Antagonists

NMDAR is believed to have a dominant role in the pathophysiology of AD. NMDAR stimulation results in Ca 2+ influx which activates signal transduction and as a consequence, it triggers gene transcription essential for the formation of a long-term potentiation (LTP), which is important for synaptic neurotransmission, plasticity, and memory formation. Over-activation of NMDARs causes an abnormal level of Ca 2+ signaling and overstimulation of glutamate, which is the primary excitatory amino acid in the CNS, which results in excitotoxicity, synaptic dysfunction, neuronal cell death, and a decline in cognitive functions. Several NMDAR uncompetitive antagonists have been developed and entered clinical trials, however, most of them failed due to low efficacy and side effects. Memantine ( 5 , Figure 4 ) is the only approved drug in this category to treat moderate to severe AD; in addition, other NMDAR uncompetitive antagonist compounds are being developed, such as RL-208 (3,4,8,9-tetramethyltetracyclo [4.4.0.0 3,9 .0 4,8 ]dec-1-yl)methylamine hydrochloride), a polycyclic amine compound that may possess a promising therapeutic effect in age-related cognitive problems and AD [ 115 , 116 , 117 ].

Memantine ( 5 , Figure 4 ) is a low-affinity uncompetitive antagonist of the NMDAR, a subtype of glutamate receptor that prevents over-activation of the glutaminergic system involved in the neurotoxicity in AD cases. Memantine is used for the treatment of moderate to severe AD alone or in combination with AChEI. The drug is safe and well-tolerated, it blocks the excitatory receptor without interfering with the normal synaptic transmission due to memantine’s low affinity, where it is displaced rapidly from NMDAR by high concentrations of glutamate, thus avoiding a prolonged blockage. The latter is associated with high side effects, especially on learning and memory [ 99 , 118 ].

6.2. Promising Future Therapies

6.2.1. disease-modifying therapeutics (dmt).

Disease-modifying treatment or therapy (DMT) alter the progression of AD by working on several pathophysiological mechanisms. This is in contrast to symptomatic therapy which works on improving the cognitive functions and decreasing symptoms such as depression or delusions without affecting or modifying the disease. DMTs, either immunotherapies or small molecules, are administrated orally and are being developed to prevent AD or decrease its progression. Several DMTs have been developed and entered the clinical trials, such as AN-1792, a synthetic Aβ peptide (human Aβ 1–42 peptide of 42-amino acids with the immune adjuvant QS-21) and the first active immunotherapy for AD which entered phase II clinical trials and discontinued due to a meningoencephalitis side effect in 6% of the patients. Other drugs were also developed and failed in the clinical trials, including the anti-Aβ antibody (solanezumab and bapineuzumab), γ-Secretase inhibitors (semagacestat 6 , avagacestat 7 , and tarenflurbil 8 ) ( Figure 4 ) and β-secretase inhibitors (BACE) (Lanabecestat 9, verubecestat 10 , and atabecestat 11 ) ( Figure 4 ). DMTs failures are due to several factors, such as starting therapy too late, giving treatment for the wrong main target, use of inappropriate drug doses, and misunderstanding of the pathophysiology of AD. Several immunotherapies described in Table 1 have been developed over decades, including: CAD106, an active Aβ immunotherapy that induces Aβ antibodies in animal models and consists of multiple copies of Aβ1–6 peptide coupled to Qβ coat protein, a virus-like particle, and is still in clinical trials, and CNP520 (umibecestat, 12 ) ( Figure 4 ), a small molecule that inhibits beta-scretase-1 (BACE-1) and therefore inhibits Aβ production. CNP520 was found to reduce Aβ plaque deposition and Aβ levels in the brain and CSF in rats, dogs, and healthy adults ≥ 60 years old, and is still under clinical trials. Furthermore, aducanumab, gantenerumab, and crenezumab are all human Aβ monoclonal antibody that bind with high affinity to aggregated Aβ, and they are still under study in the clinical phases with other DMTs described in Table 1 [ 6 , 119 , 120 , 121 , 122 , 123 , 124 ].

Disease modifying agents for the treatment of Alzheimer’s disease in clinical trials.

Another class targeting the α-secretase enzyme was developed and has been considered as therapeutic agents. α-secretase modulators or activators stimulate the cleavage of APP. There is little knowledge about the activation pathway, but research assumes that it is promoted by the phosphatidylinositol 3-kinase (PI3K)/Akt pathway or by γ-aminobutyric acid (GABA) receptor signaling. Targeting these pathways may give potential therapeutic agents for AD [ 6 ].

In addition to the anti-amyloid agents, the tau aggregation inhibitors are another promising DMT. The tau is a biomarker for neurofibrillary tangles (NFT) in AD and naturally modulates microtubule stability, signaling pathways, and axonal transport. A modification in tau conformation results in toxic aggregation. Therefore, the prevention of tau aggregation becomes an interesting approach for drug discovery to reduce AD progression. Studies in mice have shown that tau oligomers cause mitochondrial damage, disruption of neuronal signaling, synaptic loss, and memory impairment. Disease-modifying therapeutics (DMT) like small molecules can be used to inhibit the initial step in the tau aggregation and thereby reduce its accumulation. Methylene blue ( 13 , Figure 4 ) is a blue dye that inhibits the tau aggregation and entered phase II clinical trials to treat mild to moderate AD. Upon administration of the drug, the color of the urine becomes blue, which indicates a lack of binding, and because of that, the study was highly criticized. Other approaches suggest that an inhibition of specific kinases such as glycogen synthase kinase 3 (GSK3β) can inhibit tau hyperphosphorylation and block tau deposition. Examples of these entities include tideglusib ( 14 , or NP-031112 (NP-12), Figure 4 ), a thiazolidinedione-derived compound, lithium, pyrazolopyridines, pyrazolopyrazines, sodium valproate, and others. Another protein kinase inhibitor is saracatinib (AZD0530) ( 15 , Figure 4 ), which acts by inhibiting tyrosine kinase and has shown good results in improving memory in transgenic mice and is currently in phase II trials [ 125 , 126 , 127 ]. Davidowitz et al. utilized the hatu mouse model of tauopathy to study the efficacy of a lead small molecule in preventing tau accumulation. The study results demonstrated a significant reduction in tau levels and its phosphorylated form levels, which indicates the ability to inhibit the entire pathway of the tau aggregation by using an optimized lead compound [ 128 ].

6.2.2. Chaperones

Protein misfolding caused by mutations or environmental factors results in aggregations that are toxic, and their accumulation causes neurodegenerative disorders like AD. Naturally, cells develop protein quality control (PQC) systems that inhibit protein misfolding before exerting their toxic effects. With age, this balance is altered and the misfolded shapes overwhelm the PQC system, which in turn activates the unfolded protein response (UPR) that stops the protein synthesis and increases chaperone production. Generally, the cells in humans have proteins that are responsible for other proteins to function and arrive to their destination in the cell. These proteins are called “chaperones”. Chaperones are involved in protein folding and improvement of the PQC system efficiency. Therefore, it is considered a promising candidate for treating neurodegenerative diseases. It can be classified into three groups: (1) molecular chaperones, which are proteins that assist other nonnative proteins in their folding or unfolding, like overexpression of heat shock proteins (Hsps) that serve as neuroprotective agents, (2) pharmacological chaperones, which are low molecular weight compounds (enzymes or receptor-ligand or selective binding molecules) that induce refolding of proteins, stabilize their structure, and restore their function, and (3) chemical chaperones, also low molecular weight compounds, which are divided into two groups, osmolytes and hydrophobic compounds. The members in these two groups have no specific mechanism of action and need high concentrations to exert their therapeutic effects [ 129 ].

• Heat Shock Proteins (Hsps)

The causes for most neurodegenerative diseases are protein misfolding and aggregation, which lead to cell death. The molecular chaperone can be intracellular, such as in the case of heat shock proteins (e.g., Hsp40, Hsp60, Hsp70, Hsp90, Hsp100, and Hsp110), and extracellular, such as clustering and alpha-macroglobulin. HSPs play an essential role in the protein folding process and protect cells from harmful stress-related events. There are two families of Hsps: (a) classic Hsps that possess an ATP-binding site with a molecular weight of 60 kD or more. This family includes Hsp100, Hsp90, Hsp70, and Hsp60, and (b) the small Hsps such as αB-crystalline, Hsp27, Hsp20, HspB8, and HspB2/B3 that lack ATP-binding site, with a molecular weight of 40 kD or less. These proteins can assist other Hsps in their refolding function. Failure of these mechanisms can lead to oxidative stress, mitochondrial dysfunction, and many other conditions that cause damage, a loss of neurons, and a progression of neurodegenerative diseases. Different HSPs can block the aggregation process of misfolded proteins, like amyloidogenic proteins (Aβ and tau), and promote their degradation [ 130 , 131 ].

Hsp60 plays an important role in mitochondrial protein folding. Its role in AD is not clear, some believe that the protein has a protective role and others think it has a harmful effect where it can be over-expressed by activated microglia, which increases pro-inflammatory factors such as toll-like receptor 4 (TLR-4) that stimulate neuronal cell death. Therefore, inhibiting activated microglia and Hsp60 expression is a promising strategy for preventing neurodegenerative diseases. Examples of compounds that inhibit Hsp60 are mizoribine (Immunosuppressant) ( 16 , Figure 5 ) and pyrazolopyrimidine EC3016 ( 17 , Figure 5 ). Both compounds act by blocking ATPase activity of Hsp60 and inhibiting protein folding. On the other hand, avrainvillamide, a fungal metabolite ( 18 , Figure 5 ), and epolactaene, a bacterial metabolite ( 19 , Figure 5 ), act by binding to the Hsp60′s cysteine residues and inhibit its folding activity. However, Hsp60’s role in AD remains controversial and there is a need for more investigations to understand its role [ 130 ].

The chemical structures of different chaperone molecules: Mizoribine 16 , EC3016 17 , Avrainvillamide 18 , Epolaztaene 19 , MKT-077 20 , YM-01 21 , JG-98 22 , Radicicol 23 , Geldanamycin 24 , 17-AAG 25 , Pochoxime C (OS47720) 26 , R55 27 , and OT1001 28 .

Studies have shown that Hsp70 binds to Aβ42 and prevents self-aggregation. Martín-Peña et al. studied two isoforms of Hsp70, cytosolic and extracellular, in Drosophila flies AD models and evaluated their protective role against memory decline that results from Aβ42 aggregation. The animal studies showed that Hsp70 has a dual function: intracellularly and extracellularly, where it protects against Aβ42 neurotoxicity and synaptic loss. In addition to its ability to bind to tau and its hyper-phosphorylated form and prevent its formation, it decreases aggregation and promotes tau binding to microtubules. Hsp70 acts by activating microglia, insulin-degrading enzyme, and tumor growth facto r- β1, which degrades β-amyloids and prevents memory impairments [ 132 , 133 ]. Some studies in AD brain tissue demonstrated an overexpression of Hsp70 levels and a correlation with the presence of activated glia and stressed neurons. Also, it was found that Hsp70 is associated with extracellular deposits in AD. Drug therapies targeting Hsp70, mainly referring to previous anticancer drugs which target and inhibit Hsp70 ATP-binding site, are considered as candidates in AD treatment due to their ability to reduce tau levels in vitro and ex vivo. MKT-077(1-ethyl-2-(( Z )-(( E )-3-ethyl-5-(3-methylbenzo [ d ]thiazol-2(3 H )-ylidene)-4-oxothiazolidin-2-ylidene)methyl)pyridin-1-ium chloride) ( 20 , Figure 5 ), is an anticancer rhodacyanine compound that binds to mortalin, a mitochondrial Hsp70 site, and acts as an anti-proliferative agent, but the use of this compound was stopped due to toxicity side effects and low BBB penetration. On the other hand, YM-01 ( 21 , Figure 5 ), a more potent MKT-077 derivative, was developed with a single replacement of the ethyl group on the pyridinium nitrogen of MKT-077 with a methyl group. JG-98 ( 22 , Figure 5 ) is also an MKT-077 derivative with a 60-fold higher binding affinity to Hsp70 than YM-01 [ 130 , 134 , 135 , 136 ].

Hsp90 is another type of HSP that regulates the tau phosphorylation and dephosphorylation. An inhibition of Hsp90 results in a decrease in phosphorylation of tau due to a reduction in tau kinases, which is thought to be responsible for tau pathogenesis when it is hyperactivated. Hsp90 inhibitors are used for cancer therapy, but recently, they are considered as promising therapy for AD. Radicicol (RDC) ( 23 , Figure 5 ) and geldanamycin (GA) ( 24 , Figure 5 ) are Hsp90 inhibitors. GA is a natural antifungal compound and the first discovered Hsp90 inhibitor. Studies on this inhibitor were stopped due to its toxicity. On the other hand, 17-AAG (17-(Allylamino)-17-demethoxygeldanamycin) ( 25 , Figure 5 ) is a GA derivative with a lower toxicity and better pharmacokinetic profile that showed a good improvement of the cognitive function by inducing other HSPs, like Hsp70, in addition to reducing NFTs in the transgenic mouse model by blocking the tau phosphorylation pathway, indirectly [ 137 , 138 ]. Pochoxime C (OS47720) ( 26 , Figure 5 ) is also a CNS-permeable Hsp90 inhibitor that showed good safety and efficacy profiles when tested in the AD mouse model. Studies revealed that OS47720 acts by strengthening synaptic function via heat shock factor (HSF-1) activation and dependent transcriptional events [ 139 ].

The combined studies demonstrate that targeting HSPs is a promising strategy to develop drugs with a new mechanism of action for reducing pathogenic tau levels and restoring normal tau homeostasis.

• Vacuolar sorting protein 35 (VPS35)

An accumulation of proteins in neurons and glial cells leads to disturbance of cellular protein homeostasis. The endosomal-lysosomal system is responsible for transporting proteins for recycling and degradation. Any malfunction in the system can lead to several diseases, such as Alzheimer’s disease. Retromer is a complex of regulator proteins composed of sorting nexin (SNX1, 2, 5, 6) and vacuolar sorting proteins (VPS 26, 29, 35), which are responsible for transporting cargo molecules from the endosome to the trans -Golgi network. A loss of retromer’s function results in the downregulation of VPS35, which can increase Aβ formation, induce cognitive impairments, and cause synaptic dysfunction, which is reported in AD patients [ 140 , 141 ]. A study on 3xTg mice brains was conducted to evaluate the effect of VPS35 overexpression on memory function. The study showed that a significant reduction of the Aβ peptide and tau neuropathology (soluble, insoluble, and phosphorylated tau) was associated with overexpression of VPS35, in addition to a reduction in neuroinflammation and ameliorating synaptic dysfunction [ 142 ]. Therefore, VPS35 is an important promising therapeutic target for AD treatment. A small pharmacological chaperones molecule called R55 (thiophene-2,5-diylbis(methylene) dicarbamimidothioatedihydrochloride) ( 27 , Figure 5 ), a thiophenethiourea derivative, can enhance retromer stability and function by increasing retromer proteins, shifting AOO from the endosome, and reducing pathogenic processing of APP, which may serve as a promising therapeutic molecule for neurodegenerative diseases [ 143 ].

Studies demonstrated that the accumulation of gangliosides has been associated with misfolding and aggregation of proteins in neurodegenerative diseases. Abnormal levels of mono-sialoganglioside (GM1, GM2, and GM3) have been reported in AD brains. Mutant forms of Aβ, like Dutch mutant APPE693Q, showed susceptibility to pro-aggregation properties of GM2 and GM3, resulting in the formation of Aβ peptides complexes with gangliosides (ganglioside-bound Aβ (GAβ) peptide) and subsequently leading to an acceleration of aggregation and accumulation of Aβ peptides.

β-hexosaminidase (β-hex) is a lysosomal enzyme that acts by catabolizing GM2 ganglioside, and increasing its activity can lead to a reduction of GM2 levels and Aβ aggregation and accumulation. Small molecules like pharmacological chaperones (PC) can selectively bind and stabilize wild-type proteins and restore their normal folding. OT1001 ( 28 , Figure 5 ) is an iminosugar PC that targets β-hex and increases its level in the brain and reduces GAβ pathology. Studies on Dutch APPE693Q transgenic mice showed that OT1001 has good pharmacokinetics, brain penetration ability, and tolerability, with lower side effects. These make the compound a good drug candidate for increasing the β-hex activity [ 144 ].

6.2.3. Natural Extract

For a long time, natural compounds have been used as therapeutic agents for several pathological diseases, and recent studies showed that they possess a neuroprotective effect. In vitro and in vivo studies have proven that natural compounds possess a therapeutic potential for AD, which allowed some of them to enter the clinical trials stages. Nicotine was the first natural compound entered in the clinical trials for AD, then other compounds like vitamins C, E, and D gained more attention and interest due to their protective role against neuroinflammation and oxidative damage. Recently, bryostatin, a macrolide lactone extract from bryozoan Bugula neritina, has been evaluated and showed the ability to induce α-secretase activity, reduce Aβ production, and enhance the learning and memory in an AD mice model [ 145 ]. Other natural compounds used in folk medicine (traditional Chinese medicine (TCM)) demonstrated a great potential in treating AD by acting on several mechanisms, as shown in Table 2 below [ 146 ].

Natural compounds used in folk medicine and their mechanism of actions.

7. Conclusions

Alzheimer’s disease is now considered a world health concern; as a consequence, the National Institute on Aging—Alzheimer’s Association reclassified and updated the 1984 NINCDS-ADRDA criteria for higher specificity, sensitivity, and early identification of patients at risk of developing AD. Several criteria have been proposed for a more accurate diagnosis of AD, including clinical biomarkers, bodily fluids, and imaging studies. Despite that, the treatment of AD remains symptomatic, without alteration in the disease’s prognosis. Inhibitors to cholinesterase enzyme such as galantamine, donepezil, and rivastigmine, and NMDA antagonists such as memantine, improve memory and alertness but do not prevent progression. Several studies have shown that modification in lifestyle habits like diet and exercise can improve brain health and reduce AD without medical intervention and is considered as a first-line intervention for all AD patients. Recently, the research is focusing on targeting the pathological features of AD such as Aβ and p-tau. Future therapies such as disease-modifying treatment can alter the progression of AD by targeting the Aβ pathway, and many drugs have entered the clinical trials, like AN-1792, solanezumab, bapineuzumab, semagacestat, avagacestat, and tarenflurbil, but failed in demonstrating efficacy in the final clinical stages. Other DMTs are still under investigation, such as those targeting Aβ and tau pathologies, such as aducanumab, gantenerumab, crenezumab, tideglusib, lithium, and others. Other promising compounds called chaperones like heat shock proteins and vacuolar sorting protein 35 (VPS35) function by assisting other proteins to function normally and to arrive at their destination in the cell safely, and therefore can be used as a treatment for neurodegenerative diseases. Moreover, the natural extracts used in folk Chinese medicine showed great potential in treating AD by acting on several mechanisms’ pathways. In conclusion, the success of AD treatment depends on its early administration and patient monitoring for disease progression using biomarkers diagnosis. Future therapies that target tau pathology and the use of combination therapy may have a potential to slow the progression of AD pathology. Designing a potent, selective, and effective drug is urgently needed to treat patients with AD and those at risk for developing the disease.

Author Contributions

Literature survey and first draft writing were done by Z.B., and final draft, including the revisions, were accomplished by R.K. All authors have read and agreed to the published version of the manuscript.

This research received no external funding.

Conflicts of Interest

The authors declare no conflict of interest.

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

• Entertainment
• Environment
• Information Science and Technology
• Social Issues

Home Essay Samples Health

Essay Samples on Dementia

An organic disorder of dementia and treatment of patient.

The aim of this essay is to identify an individual who has been cared for in my practice with an organic disorder of Dementia, the purpose of chosen this topic is because Dementia is one of the most common diseases that affect older patient. The...

Geriatric Psychiatry Research: Treating Agitation in The Elderly

As the relative increase in the elderly population becomes more pronounced, there is a greater awareness of some of the problems associated with providing adequate care for this population. There is an increased need for understanding the unique needs of providing for the physical, emotional...

• Gerontology

The Main Differences Between Dementia and Alzheimer 

There are times when we fall ill; seriously ill. We visit the doctor, and they prescribe the various ways we can be healthy. However, with age our body system deteriorates. We get plagued with various diseases. As we grow old, our memory also lessens. We...

• Alzheimer's Disease
• Human Brain

Cognitive Impairment And Dementia As Health Threats To Aging Population

Title The title describes the main purpose of the study. The title of this article is well stated to enable one to note that the study will be on objectively measured physical activity and the cognitive function in older adults (Zhu et al, 2017). The...

The Struggles of Living with Alzheimer’s Disease and the Importance of an Early Treatment

Alzheimer disease is a very common illness, this disease was first found on April 10 th 1980. Around that era there was still more learning on discovering the different illnesses in the human body. The first case Alzheimer’s was discovered was in 1901 by a...

Stressed out with your paper?

Consider using writing assistance:

• 100% unique papers
• 3 hrs deadline option

Alzheimer Disease Progression and Stages

The brain is a three-pound fascinating organ that is enclosed and protected by the cerebrospinal fluid. The brain is responsible for the coordination of the human’s behavior, thoughts, and emotions. Part of the brain's information-processing network includes neurons, or cells that transmit signals throughout the...

The History of Alzheimer’s Disease, Its Symptoms and Dangers

Abstract Alzheimer’s disease is a progressive, multifactorial, neurodegenerative disorder manifested by memory and cognitive dysfunction, behavioral disturbance, progressive impairment of activities of daily living. Alzheimer’s disease is associated with the spreading of misfolded protein aggregates in the brain. However reduction in brain volume in Alzheimer...

Social Services for People Suffering from Dementia

Introduction The topic explored in this literature review will be focused on the services available for Dementia sufferers and whether more can be done. The Alzheimer’s Society defines Dementia as “A set of symptoms that may include memory loss and difficulties with thinking, problem-solving or...

• Public Health
• Public Service

Dementia: Causes, Symptoms, Diagnosis, Care, Myths

There are as range of causes of Dementia, theses can include strokes. A stroke can cause a prevention of a normal blood flow, which in turn deprives the brain cells of Oxygen. This can cause Vascular Dementia, such symptoms can include memory loss, problems with...

• Mental Disorder

Nursing Care Plan for Patients with Dementia

Dementia is identified by the client struggling with both cognitive and noncognitive symptoms, the Cognitive symptoms largely signify an impairment in communication, reasoning, visuospatial function, the lack of capacity to have a conversation, and related mental activities, leading to the decline in the brains function....

Best topics on Dementia

1. An Organic Disorder of Dementia and Treatment of Patient

2. Geriatric Psychiatry Research: Treating Agitation in The Elderly

3. The Main Differences Between Dementia and Alzheimer 

4. Cognitive Impairment And Dementia As Health Threats To Aging Population

5. The Struggles of Living with Alzheimer’s Disease and the Importance of an Early Treatment

6. Alzheimer Disease Progression and Stages

7. The History of Alzheimer’s Disease, Its Symptoms and Dangers

8. Social Services for People Suffering from Dementia

9. Dementia: Causes, Symptoms, Diagnosis, Care, Myths

10. Nursing Care Plan for Patients with Dementia

• Mental Illness
• Teenage Pregnancy
• Chronic Pain
• Borderline Personality Disorder
• Eating Disorders
• Readmission
• Homeostasis

Need writing help?

You can always rely on us no matter what type of paper you need

*No hidden charges

100% Unique Essays

Absolutely Confidential

Money Back Guarantee

By clicking “Send Essay”, you agree to our Terms of service and Privacy statement. We will occasionally send you account related emails

You can also get a UNIQUE essay on this or any other topic

Thank you! We’ll contact you as soon as possible.

An official website of the United States government

Here's how you know

The .gov means it’s official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

What Is Alzheimer's Disease?

Alzheimer’s disease is a brain disorder that slowly destroys memory and thinking skills and, eventually, the ability to carry out the simplest tasks. In most people with the disease — those with the late-onset type symptoms first appear in their mid-60s. Early-onset Alzheimer’s occurs between a person’s 30s and mid-60s and is very rare. Alzheimer’s disease is the most common cause of dementia among older adults.

The disease is named after Dr. Alois Alzheimer. In 1906, Dr. Alzheimer noticed changes in the brain tissue of a woman who had died of an unusual mental illness. Her symptoms included memory loss , language problems, and unpredictable behavior. After she died, he examined her brain and found many abnormal clumps (now called amyloid plaques) and tangled bundles of fibers (now called neurofibrillary, or tau, tangles).

These plaques and tangles in the brain are still considered some of the main features of Alzheimer’s disease. Another feature is the loss of connections between nerve cells (neurons) in the brain. Neurons transmit messages between different parts of the brain, and from the brain to muscles and organs in the body. Many other complex brain changes are thought to play a role in Alzheimer’s, too.

How many Americans have Alzheimer’s disease?

Estimates vary, but experts suggest that more than 6 million Americans age 65 and older may have Alzheimer’s. Many more under age 65 also have the disease. Unless Alzheimer's can be effectively treated or prevented, the number of people with it will increase significantly if current population trends continue. This is because increasing age is the most important known risk factor for Alzheimer’s disease.

What does Alzheimer’s disease look like?

Memory problems are typically one of the first signs of Alzheimer’s, though initial symptoms may vary from person to person. A decline in other aspects of thinking, such as finding the right words, vision/spatial issues, and impaired reasoning or judgment, may also signal the very early stages of Alzheimer’s disease. Mild cognitive impairment (MCI) is a condition that can be an early sign of Alzheimer’s, but not everyone with MCI will develop the disease.

People with Alzheimer’s have trouble doing everyday things like driving a car, cooking a meal, or paying bills. They may ask the same questions over and over, get lost easily, lose things or put them in odd places, and find even simple things confusing. As the disease progresses, some people become worried, angry, or violent.

How long can a person live with Alzheimer’s disease?

Alzheimer’s disease is currently ranked as the seventh leading cause of death in the United States, but the time from diagnosis to death varies. It may be as little as three or four years if the person is older than 80 when diagnosed, to as long as 10 or more years if the person is younger.

Currently, there is no cure for Alzheimer’s disease, though there has been significant progress in recent years in developing and testing new treatments. Several medicines have been approved by the U.S. Food and Drug Administration to treat people with Alzheimer’s.

Learn more about how Alzheimer's disease is treated .

You may also be interested in

• Reading more about the signs of Alzheimer's disease
• Exploring myths and facts about Alzheimer's disease
• Learning more about different types of dementia

Sign up for email updates

Receive weekly tips and resources on Alzheimer's disease and related dementias from NIA's Alzheimers.gov

For more information about Alzheimer's disease

NIA Alzheimer’s and related Dementias Education and Referral (ADEAR) Center 800-438-4380 [email protected] www.nia.nih.gov/alzheimers The NIA ADEAR Center offers information and free print publications about Alzheimer’s and related dementias for families, caregivers, and health professionals. ADEAR Center staff answer telephone, email, and written requests and make referrals to local and national resources.

Alzheimers.gov www.alzheimers.gov Explore the Alzheimers.gov website for information and resources on Alzheimer’s and related dementias from across the federal government.

Eldercare Locator 800-677-1116 [email protected] https://eldercare.acl.gov

MedlinePlus National Library of Medicine       www.medlineplus.gov

This content is provided by the NIH National Institute on Aging (NIA). NIA scientists and other experts review this content to ensure it is accurate and up to date.

Content reviewed: July 8, 2021

nia.nih.gov

An official website of the National Institutes of Health

Introduction

A care plan for dementia, interventions, recommendation.

Dementia participants or residents will possess a care plan for Dementia which portrays more personal details. The care plan is designed to motivate people living with this condition. It is laid down to help the caregivers in understanding the patient (Royston, Mitchell, Sheeran, Strain & Goldsmith, 2017). The following is a care plan for Kelly, a patient who has Dementia.

Kelly often engages in intrusive conducts during the day such as snatching things that are not hers; she can take somebody’s hat off their heads and walk away.

Frequently she gets agitated especially in the afternoons when she insists or wants to go home.

• To improve the intrusive or meddling behavior via diverse strategies
• To enhance the efficiency of a two-way communication
• To elicit positive responses from Kelly towards specific planned activities.
• To intervene in her feeding habits
• Caretakers will communicate with Kelly in a relaxed and calm way and offer empathetic encouragement while at the same time, give her adequate time for expressing herself (Smart, 2014).
• Kelly will engage in various daily living activities severally during the day to minimize intrusive behaviors for example
• Folding clothes
• Dusting and wiping shelves
• Combing her hair and setting it
• Washing dishes
• The staff will focus on spending a one on one time with Kelly in the evening taking her out for walks while engaging her in conversations regarding something she used to love in order to reduce her cognitive stress.
• Kelly will participate in something she enjoys for at least four times a week like dancing to the sound of music (country).
• She will also assist staff in preparing church services.
• She will be fed and taught how to feed herself well.

1. Cole, D. (2012). Optimizing nutrition for older people with dementia. Nursing Standard, 26(20), 41-48.

2. Pulsford, D., & Thompson, R. (2013). Dementia. London: Jessica Kingsley Publishers.

3. Royston, C., Mitchell, G., Sheeran, C., Strain, J., & Goldsmith, S. (2017). Optimisation of dementia care in care homes: Dementia care framework (innovative practice). Dementia, 147130121774000. doi: 10.1177/1471301217740009

4. Smart, C. (2014). MINDFULNESS TRAINING: A NOVEL APPROACH TO INTERVENING IN OLDER ADULTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer’s & Dementia, 10(4), P164. doi: 10.1016/j.jalz.2014.04.158

• Alzheimer Disease
• Anger Management

A moving essay on dementia in the lancet

By Maura Gallahue

There is hope…

In an era where stigmatisation that surrounds dementia remains a global problem that requires global action, Dana Walrath , Atlantic Fellow for Equity in Brain Health, together with Prof. Brian Lawlor , Deputy Executive Director of Global Brain Health Institute, trace some of the social origins of dementia stigma in essay published in The Lancet on September 21. Here, they reflect on a new republic of hope for dementia. A hope that challenges the stigma, breaks down barriers, and focuses on restoring personhood for the patient diagnosed and also their care partners.

To coincide with World Alzheimer’s Day, this essay looks at how dementia challenges us as a society to examine what it means to be human. The authors provide readers with an uplifting lens through which to understand the idea of hope and connection and to recognise the persistence of human qualities that reveal proximity to our essential humanity.

“Seeing dementia as a diversity issue, as a different way of being, allows those living with it to be our teachers,” write Lawlor and Walrath. “This approach confers hope, honour, and respect to people living with this disease.”

Read this article on The Lancet: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(19)32099-9/fulltext

Spread the news

Share this article if you found it interesting..

Atlantic Fellows Newsletter

Thank you for subscribing..

Expect to see updates in your inbox in the coming weeks.

We care about your data, and we'd use cookies only to improve your experience. By using this website, you accept our cookie policy. Read our Privacy Policy here .

By Maura GallahueThere is hope…In an era where stigmatisation that surrounds dementia remains a global problem that requires global action, Dana Walrath, Atlantic Fellow for Equity in Brain Health, to

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

• WRITING CENTER
• CUSTOMER AREA
• Client Reviews
• Our Writers
• Sample Papers
• Study Resources

Get Your Grades Improved by Our Professional Writers - We are Trusted by Thousands of Students!

Global compose inc. constantly employs professional homework writing help writers from usa, uk, ca and au. the writers are highly trained professionals, comprising of 500+ masters and ph.d level writers available 24/7. we assist clients who either have difficulty completing their assignments, sick or in need family time. to get started, submit your instructions., calculate your order price.

Use Discount Code: FIRST5 at Checkout FIRST5 -->

PRICE BEFORE DISCOUNT: $15.00

• Essay Writing Examples

Sample Essay Assignment on Dementia

Get homework help on this topic - check the quality of writing from this sample, if you are looking for assignment help on this topic or similar topic, click on order now button to submit your details. once we have your order details, your assignment will be assigned to one of our best writers, who will then proceed to write your paper and deliver it within your specified deadline. thank you for choosing us today.

Dementia is a term that is used to describe a host of brain diseases. Dementia gives a description of a variety of symptoms that are related to memory lapse and imparity of thinking skills. As a result of the symptoms, a person’s ability to carry out daily activities normally is significantly reduced. Some of the most common brain diseases that result from these symptoms are Alzheimer’s disease and vascular dementia.

Causes of Dementia

Dementia can occur as a result of a variety of situations that cause brain cells damage. Below are some of the most commonly known causes.

• Infections that cause loss of nerve cells in the brain like Huntington’s and Alzheimer’s Parkinson’s.
• Diseases that affect the blood vessels like stroke. Such can lead to disorders called multi-infarct dementia
• Nutritional deficiencies like Vitamin B12 and lack of folate.
• Toxic reactions like drug abuse and excessive consumption of alcohol.
• Health conditions that affect the brain and the spinal cord like AIDS dementia complex and Creutzfeldt-Jakob disease.
• Head injuries
• Health conditions that affect certain body organs like liver, kidney and lungs can also cause dementia
• Accumulation of fluids in the brain can also cause dementia

It is believed that between 50 to 60 percent of dementia cases are as a result of Alzheimer’s disease. Recent studies have also indicated that Pick’s disease and Lewy body diseases can also lead to dementia.

Symptoms of Dementia

People with dementia can show a variety of signs; however, the most predominant of all is that the affected person usually has a problem of memory lapse. This is because the condition impairs the person’s thinking and reasoning abilities. Below are other symptoms that can be used to judge whether a person is suffering from dementia or not.

• Communication and language imparity
• Inability to pay attention and focus
• Impaired visual perception

It is important to note that going through the experience of making impaired judgment and reasoning does not automatically mean that a person is suffering from dementia.

It is advisable that you immediately see a doctor if you or your loved one begins show signs that are similar to those of dementia.

Many cases of dementia are progressive; they start out slowly and worsen as time advances. By seeking professional help in time, a doctor is able to detect a treatable condition and offer the best remedy before the mater gets out of hand.

In case diagnosis results reveal that you are suffering from dementia, you will be placed under medication. However, the treatment will be based upon the cause since there are various kinds of brain diseases that are associated with this health condition. In the case of Alzheimer’s disease, there is neither a cure nor any treatment that can slow down the progression. However, the patient can be given certain medications to assist in the improvement of symptoms. In order for one to stay healthy and prevent the risk of contracting dementia, it is advisable to avoid cardiovascular risk factors, and engage in physical exercise and proper dieting.

Sample Essay Assignment on Dementia: References

Was this Sample Essay Assignment on Dementia useful? Would you like to get further assistance with your assignment? Contact us today; We are  a leading academic research company, with a range of  specialized services . From General Essays to PhD Thesis, we guarantee your holistic help. Our prices are affordable and competitive. What is more,  we have  a collection of sample papers in every field just for you. Place your  ORDER NOW ! You may want to consider checking our Essay Writing Services , Research Paper , Thesis Writing Services , Coursework Help , among others.

https://www.alz.org/what-is-dementia.asp#treatment

https://www.webmd.com/alzheimers/guide/alzheimers-dementia

Do you have an Assignment on a Similar or Related Topic? We can Help You Right Now! Click on the Order Now button...

Are you looking for homework writing help on this topic? This question was posted by one of our client seeking homework help.  If you are therefore looking for an assignment to submit, then click on  ORDER NOW button or contact us today. Our Professional Writers will be glad to write your paper from scratch, and delivered within your deadline. Perfect choice for your excellent grades! www.globalcompose.com.

We ensure that assignment instructions are followed, the paper is written from scratch. If you are not satisfied by our service, you can either request for refund or unlimited revisions for your order at absolutely no extra pay. Once the writer has completed your paper, the editors check your paper for any grammar/formatting/plagiarism mistakes, then the final paper is sent to your email.

Writing Features

Affordable Writing Services

Experienced Writing Team

24/7 Team of Writers

Professional E ssay Writers

Quality Measures

Trained Support Team

Non-Plagiarized Papers

Well Researched Papers

Free Writing Resources

Privacy | Confidentiality

We do not share your personal information with any company or person. we have also ensured that the ordering process is secure; you can check the security feature in the browser. for confidentiality purposes, all papers are sent to your personal email. if you have any questions, contact us any time via email, live chat or our phone number., our clients testimonials, a team of +500 masters and ph.d level homework writing help writers available 24/7 cannot get it wrong. the following are customer reviews about the quality of our services..

“Thanks for offering your professional assistance on this one. Topic was confusing but writer worked it out”

Added 24 Minutes Ago

“Thanks, I like the literature review, it is discussed in depth. Have looked at the results section and it is conclusive as I expected. Thank you”

Added 12 Hours Ago

“I like the discussion on the case study. Thank you. Am satisfied and wanted to request that same writer will handle my future assignments”

Added 30 Minutes Ago

“I was paranoid about online writing services, but on this one, the results are evident that you are much better. Will order more papers”

Added 3 Minutes Ago

“I think the paper is alright. If I can book the writer for the soon upcoming assignment, it will be great. Thanks”

Added 6 Minutes Ago

Why choose our homework writing help, we try to work as diligent as we can to help you meet your homework’s deadline. our support staff is always online 24/7 to help clarify any issues or concerns you have regarding our services. talk to us today to find out how our writers may be of help to you., customized papers, we consider your instructions and specifications in order to tailor the paper to suit your expectations., only professional writers, all our writers have a masters or ph.d and are well trained to handle assignments in various disciplines at different education levels., fast and reliable, our writers are capable of handling any assignment with short deadline and deliver without any delay, thus saving you time and energy, round the clock support, our customer support is always ready to offer real time assistance of day and night, through email, live-chat and phone., cost effective prices, we save you money with our affordable prices and huge discounts on all assignments., 100% original papers, all our papers are thoroughly researched and written from scratch. be sure of completely non-plagiarized papers., our ordering process, to get started with our homework writing help, simply click on the order now button. its easy, secure and takes less than 2 minutes to complete. the following steps illustrates the entire process., fill the order form: include all instructions and files for your assignment., submit your payment via card or paypal so that your order can be processed., a writer works on your paper and submits to editors upon completion., the completed paper is examined by our editors, then sent to your email, want to learn from experts check the writing tips below.

Final Paper Assignments

• Thesis Writing Help
• Dissertation Chapters
• Writing Research Papers
• Project Writing
• Term Paper Writing
• Speech Writing

Weekly Assignments

• Essay Writing
• Coursework Writing
• Assignment Writing Help
• Homework Writing Help
• Book Review Writing
• Movie Review Writing

Creative Assignments

• Power Points Preparation
• Analyzing Case Studies
• Creative Writing Papers
• Critical Thinking Writing
• Annotated Bibliography
• Capstone Project Writing

Admission Papers

• Writing Scholarship Essay
• Writing Admission Essays
• Writing Application Essays
• Writing Entrance Essays
• Personal Statement Essays
• Reaction Paper Writing

Samples of our Writing Illustrated Below

We have compiled a list of samples written by our writers for your review. you can use these samples to write your paper. you must however cite the source properly. if you are looking for a non-plagiarised paper, click on the order button. our professionals will work on your order. are you looking for writing tips check the list on this page. we are glad that we could help..

• Discussion Essay Homework
• Dissertation/Thesis Writing
• Book Review Paper
• Business Plan Homework
• Capstone Project Paper
• Creative Writing Homework
• Critical Thinking Homework
• Application Essay Homework
• Case Study Homework
• Literature Review Homework
• Personal Reflection Homework
• Reflection Essay Homework
• Research Proposal Homework
• Annotated bibliography Paper
• Article Review Homework
• Research Paper Homework
• Movie Review Sample
• Term Paper Sample
• Admission Essay Homework
• Argumentative Essay Paper
• Response Essay Homework

A List of Related Papers On This Category is Provided Below

• Sample Essay on European Union
• Essay Sample on the World War II experience of Japanese Americans
• Sample Essay on Diversity
• Sample Essay on Beloved Essay
• Sample Essay Writing Paper on Bullying
• Sample Al Capone Essay
• Sample Essay on the International Women’s Day
• Sample Essay on College essay on the battle royal
• Sample Essay on Avian Flu
• Sample Essay Writing Paper on Semester Review
• Sample Essay Writing Paper on Macro Social Work
• Essay Sample on Importance of Adding Communication
• Sample Essay Assignment on Paul Walker
• Sample Essay Writing Paper on Effects Of Social Media
• Sample Essay on Article review
• Sample Paper on Discussion Essay Criminal Justice
• Sample Essay Writing Paper on History
• Essay Sample Paper on The Adventures of Huckleberry Finn
• Sample Essay Writing Paper on Leisure
• Management Essay Sample on Organizations

Get your Homework Written by our Top-Notch Writers Now

Care of the Elderly With Dementia Essay

• To find inspiration for your paper and overcome writer’s block
• As a source of information (ensure proper referencing)
• As a template for you assignment

Ethical Issue: Deontology

Ethics of dementia care in elderly patients within scholarly literature, caring for elderly patients with dementia: guidance from rnao, the media coverage of the autonomy issue, social justice and patient autonomy in elderly people with dementia, ethical evidence-based actions for rns to promote social justice.

Patients, caregivers, doctors, and healthcare organizations face particular difficulties as a result of Alzheimer’s disease. It is noteworthy that the deontological theory of ethics states that all clinical decisions must be made with respect to guidelines and what is right, regardless of the consequences. Still, there are issues, such as the issue of autonomy, where a medical professional might put restraints on a patient’s freedom, which will be in their best interest. Thus, honoring patient autonomy while recognizing their decision-making abilities that are gradually deteriorating and maintaining the provision of quality care in compliance with fundamental ethical standards are necessary while caring for people with dementia.

The study of ethics, or ethical philosophy, entails organizing, justifying, and endorsing ideas of what constitutes appropriate and inappropriate conduct. The deontological theory basically promotes the fair treatment of patients and requires all medical professionals to comply with the rules, despite the outcome. According to this theory, whatever the outcome or any other considerations, the morality of a decision is exclusively determined by the form of the activity (Swartz, 2021). The decisions should, therefore, be made on the basis of what is most beneficial to the patient (Swartz, 2021). Without taking into account contextual factors, deontology regards behaviors as either good or bad. In these circumstances, one can think of the commandments from the Holy Scripture, which teach people not to kill, steal, or disrespect their parents (Swartz, 2021). It can be said that, similarly to commandments, Deontological principles separate right actions from wrong actions.

When speaking of the ethical issue of autonomy and restraints, it is vital to recognize how Deontology emphasizes respect and support of autonomy when it is the right decision to make. In this situation, when providing care for patients, limiting them in some kind of activities might be seen as a violation of their freedom and autonomy. However, if this is in the best interest of the patient and can prevent them from being harmed, it can be considered the appropriate choice in terms of Deontological logic.

Dementia affects those in their elderly years, and the ones who frequently have additional co-morbid conditions and behaviors linked to dementia may be more dangerous. Following the issues of restricting freedom and controlling risk are those related to the application of both physical and pharmaceutical constraints. The physical constraint may take many different forms, ranging from the application of physical force to seemingly innocent activities like barring doors or placing a chair too low for the individual to get up from (Chien et al., 2022). In this case, a restriction in whatever manner must be roughly proportional to any possible damage to the individual. Obviously, there must be a compelling cause to apply constraint, and the methods employed should be based on the inadequacies of less invasive ones (Okuno et al., 2021). Healthcare providers can think it is ideal for a patient to remain at a hospital or clinic. It is a loss of liberty when a patient is unable to leave but is always under professional care and observation (Parker, 2020). Still, it must be demonstrated that this is appropriate and in the patient’s best interests before it may be authorized.

In the end, it is noteworthy that healthcare practitioners should keep in mind that risk is an unavoidable aspect of life and that decreasing risk in one domain might raise damage in another while doing this balancing exercise. Considering that autonomy and welfare both depend on freedom, risk management should carefully consider all potential hazards and benefits when evaluating the various elements (Parker, 2020). Therefore, decisions regarding autonomy require much consideration and still rely on the patient’s best interests.

The Registered Nurses Association of Ontario (RNAO) emphasizes all practices and guidelines in their documents regarding proper patient care. RNAO (2018) provided and discussed guidelines for nurses providing care for patients living with dementia. The guidelines outline the responsibilities and roles of nurses in response to patient autonomy, privacy, and the provision of person-centered care. According to RNAO (2018), families of people living with dementia are direct partners that should be involved when providing care to people living with dementia. Registered Nurses are encouraged to provide continuous education and emotional support to families to cope with the emotional distress that accompanies the disease. During the education process, nurses are discouraged from influencing the patients or forcing them patients to choose to make decisions about the patient’s life.

RNAO is also an ardent supporter of person-centered care in caring for elderly patients with dementia. According to RNAO (2018), Registered nurses are encouraged to use evidence-based practices when treating and managing patients with dementia. RNs ought to create therapeutic relationships with patients and families, health promotion through creating awareness, and patient advocacy in the allocation of resources for better living standards (Lundberg, 2018). RNs are expected to be culturally sensitive and provide care to all patients regardless of age, gender, or social status.

Ethical issues in healthcare are often discussed in the media, focusing on the presumed negligence of medical personnel. For instance, Waterloo News discussed the practices of medical personnel when treating patients with dementia in one of the Canadian hospitals. The article emphasized how one study found that older hospital patients are more likely than their younger counterparts to receive restrictive treatments such as acute control drugs and medication in non-emergency scenarios (Waterloo News, 2022). Between 2005 and 2018, it was identified that there was a distinct trend of greater frequencies of these interventions being used in older persons in Ontario mental facilities (Waterloo News, 2022). In order to find out how frequently older hospital patients are constrained in non-emergency circumstances when compared to younger age brackets, researchers looked at 226,119 Ontario inpatient files over the course of these years (Waterloo News, 2022). Finally, it was accentuated that such control treatments have a number of detrimental health and psychological effects, especially in physically fragile older persons.

Obviously, in the given situation, the ethical issue of autonomy in decision-making is emphasized. Both scholarly and media materials emphasize that older patients with functional disabilities, aggressive behavior, mental retardation, and disorientation should receive treatment in accordance with their best interests. However, according to the media, before turning to such practices, person-centered and non-pharmacological management options should be considered (Waterloo News, 2022). However, the difference between scholarly material from the claim in the media is that medical personnel should make decisions in the best interest of the patients and the people surrounding them. Therefore, especially when aligned with scholarly material, such could pose a threat not only to themselves but others as well.

Whitehouse (2022) defined social justice as an approach that ensures that people living with dementia have access to resources and treatment that guarantee a life of dignity, regardless of one’s status. Social justice is all about ensuring equality and fairness in the distribution of resources and access to services. In a fair and just society, elderly patients diagnosed with dementia are allowed access to quality care regardless of social status, race, ethnic background, or gender. All people are allowed access to treatment and medications required to manage the symptoms of the condition, whether they are able to pay for the services or not. There is also a need for inclusive communities where individuals with dementia can lead comfortable lives without discrimination or stigmatization. Social justice can be attained through advocacy, where communities and physicians advocate for better programs and allocation of resources to cater for the unique needs of people that will develop dementia in the future to avoid straining the available resources.

Controversies surrounding caring for elderly patients can be addressed by Registered Nurses to promote social justice. When viewed from the perspective of social justice, care for elderly patients with dementia attracts ethical concerns that can be addressed by RNs. Bosisio and Barazzetti (2020) discussed the need for RNs to promote social justice through cultural sensitivity, bearing in mind that patients suffering from dementia can come from different races, ethnic backgrounds, and social classes. In addressing social justice, RNs are encouraged to address issues of discrimination, marginalization, and isolation of patients with dementia. Social justice can be pursued through fair and equal distribution of resources for the people in need. RNs can step in and train or educate families and caregivers on strategies that can be beneficial when living with elderly people with dementia. RNs can also advocate for the fair distribution of resources to meet the unique needs of affected individuals in society.

Dementia is increasingly becoming a healthcare concern in Canada and around the globe. The fact that more than a million Canadians are at risk of developing dementia calls for early preparation in tackling the impending problem. The condition impairs a person’s capacity to make independent and informed decisions, leading to a loss of autonomy. Loss of autonomy is an ethical concern due to the fact that every person has a right to freedom and the right to life. When other people, such as family members and physicians, make decisions on behalf of the patient, there are high chances of infringing on the patient’s rights, privacy, and freedom. RNs can advocate for patient autonomy by creating awareness, empowering families and communities, and providing psychosocial support to people living with dementia and their families. RNs should also be culturally sensitive and prepared to provide person-centered care to different populations of people suffering from dementia.

Bosisio, F., & Barazzetti, G. (2020). Advanced care planning: Promoting autonomy in caring for people with dementia . The American Journal of Bioethics , 20 (8), 93-95. Web.

Chien, C. F., Huang, L. C., Chang, Y. P., Lin, C. F., Hsu, C. C., & Yang, Y. H. (2022). What factors contribute to the need for physical restraint in institutionalized residents in Taiwan? Plos One , 17 (11), e0276058. Web.

Lundberg, K. (2018). Dementia care work situated between professional and regulatory codes of ethics . Ethics and Social Welfare , 12 (2), 133-146. Web.

Okuno, T., Itoshima, H., Shin, J. H., Morishita, T., Kunisawa, S., & Imanaka, Y. (2021). Physical restraint of dementia patients in acute care hospitals during the COVID-19 pandemic: A cohort analysis in Japan . PloS One , 16(11), e0260446. Web.

Parker, J. (2020). Ethical issues in the care of people with dementia . InnovAiT , 13 (6), 374-381. Web.

RNAO. (2018). Delirium, dementia, and depression in older adults: Assessment and care . Registered Nurses Association of Ontario. Web.

Swartz, M. H. (2020). Textbook of physical diagnosis: History and examination . Elsevier Health Sciences.

Waterloo News. (2022). Study finds excess use of non-emergency restraint among older psychiatric patients . University of Waterloo. Web.

Whitehouse, P. J. (2022). Ethical issues in dementia . Dialogues in Clinical Neuroscience . Web.

• Depressive Disorder in the Elderly
• Assessing and Planning Care for an Elderly Person
• Caring for Clients With Dementia
• "Knowing Residents With Dementia" by Kasin and Kautz
• Dementia: Non-Pharmacologic Interventions
• Health-Related Impacts of Resistance Training
• Adult Day Services and Health Equity for Older Adults Amid COVID-19
• The Risk of Falls Among the Elderly
• Aging in the United States and Japan
• Health Disparities and the Elderly
• Chicago (A-D)
• Chicago (N-B)

IvyPanda. (2024, January 20). Care of the Elderly With Dementia. https://ivypanda.com/essays/care-of-the-elderly-with-dementia/

"Care of the Elderly With Dementia." IvyPanda , 20 Jan. 2024, ivypanda.com/essays/care-of-the-elderly-with-dementia/.

IvyPanda . (2024) 'Care of the Elderly With Dementia'. 20 January.

IvyPanda . 2024. "Care of the Elderly With Dementia." January 20, 2024. https://ivypanda.com/essays/care-of-the-elderly-with-dementia/.

1. IvyPanda . "Care of the Elderly With Dementia." January 20, 2024. https://ivypanda.com/essays/care-of-the-elderly-with-dementia/.

Bibliography

IvyPanda . "Care of the Elderly With Dementia." January 20, 2024. https://ivypanda.com/essays/care-of-the-elderly-with-dementia/.

How to Write a Personal Narrative: A Step-by-Step Guide

“As I sat down to write this article, memories flooded back, each one a brushstroke in the painting of my past…”

That could be the beginning of your personal narrative. Writing it lets you turn your memories and experiences into stories that click with others. This type of writing goes beyond school assignments or essays for college applications; it’s a chance to get really good at sharing your life's events in ways that matter. 

In this article, we're going to explore what personal narratives are all about and guide you through a simple seven-step process to create your own. You’ll learn how to pull out moments that make your story stand out and how to tweak your writing until it’s just right. We’ve got practical examples for you to follow along, making sure you have everything you need to tell your story. 

What is a Personal Narrative?

A personal narrative is a way to tell your own story. It's a style of writing that puts your experiences front and center, inviting readers into your world. Teachers often assign personal narratives to encourage free, expressive writing. 

The personal narrative definition is wider than academic settings, though. . These narratives can also show potential employers who you are beyond your resume. At its core, writing a personal narrative is a form of storytelling, using a first-person perspective to bring real-life tales to life. Whether it's for a grade, a job, or just for fun, it's about getting your story out there.

Your Story, Perfected

Let our experts refine your personal narrative, making sure every detail shines and your story is both clear and impactful.

How to Write a Personal Narrative: Steps

In this section, we'll break down the process into manageable steps, starting with how to zero in on the right topic that speaks about who you are.

Step 1. Choosing a Personal Narrative Topic

The first step in crafting your personal narrative is picking the perfect topic. It should be something meaningful to you, something that has not just happened, but also shaped who you are or has a significant story behind it. Here’s how to frame your personal narrative ideas:

• Story Arc : Your narrative is like a mini-movie. Start with setting the scene, build up to the main event, and wrap up with a reflection. For example, if you’re writing about your first solo travel experience, begin with your initial feelings, describe the challenges you faced, and end with what you learned about yourself.
• Thematic Focus : Instead of moving through time, center your narrative around a central theme. Maybe it’s about resilience, and you could link different times you had to be resilient, ending with a major life challenge.
• A Day to Remember : Sometimes a single day can tell a lot about you. Pick a day that was particularly memorable and unpack it from start to finish. Maybe it was a seemingly ordinary day that brought unexpected lessons or joys.

Step 2. Working on Your Personal Narrative Outline

When putting together your personal narrative, starting with a solid outline can help keep your story on track. Here's how you can lay it all out:

• Introduction: Kick things off with a hook that grabs attention, like an intriguing question or a vivid snapshot of a key moment. Set the scene and introduce the main theme.
• Setting and Characters : Give a good sense of where your story is unfolding and who's involved. Paint a clear picture of the backdrop and the key people.
• Plot Development : Lay out the events in the order they happened, or group them around major themes. Build up to your main event, adding conflicts or challenges as you go.
• Climax : This is the high point of your story, where everything comes to a head. Make it a moment that has the most impact.
• Resolution : Wrap up the main storyline, showing how things settled down after the climax.
• Reflection : Spend some time reflecting on what happened. Share what you learned or how you changed because of the experience.

If you're looking for help crafting your personal narrative, consider checking out some legit essay writing services to get professional guidance.

Step 3. Writing the First Draft of Your Personal Narrative

Now let’s move on to the fun part! Don't worry about getting everything perfect right away — the first draft’s goal is to let your story flow naturally:

• Start with Your Hook: Revisit the introduction you outlined and flesh it out. Begin with the attention-grabbing sentence that will make readers want to continue.
• Let the Story Unfold: Follow your outline, but allow yourself some flexibility. As you write, new memories or details may come to mind. Embrace them! Think about what you saw, heard, and felt during these moments. Were you sitting in a sunlit room, listening to the hum of a busy street outside? Maybe you felt the chill of an autumn breeze? 
• Stay True to Your Voice: This is your story, so let your unique voice shine through. Whether you're humorous, reflective, or serious, maintain a consistent tone that feels authentically you. Keep the tone conversational and straightforward, as if you’re telling this story to a friend. 

Once the first personal narrative draft is done, set it aside for a bit before revisiting it with fresh eyes.

Step 4. Revising Your Personal Narrative

Once the first personal narrative draft is done, set it aside for a bit before revisiting it with fresh eyes:

• Tighten Up the Story : As you go through your draft, focus on making everything clear and to the point. If you’ve talked about how nervous you were before a big event more than once, try to combine those thoughts into one powerful sentence that really captures how you felt.
• Keep Your Tone Consistent : Make sure your voice stays the same throughout the story. If you start off with a casual, conversational tone, like saying, “I couldn’t shake the nerves before my big test,” stick with that style instead of suddenly becoming formal later on.
• Adjust the Pacing : Pay attention to how smoothly your story flows from one part to the next. When you’re describing a key moment, like meeting someone important or going through a major experience, give it the detail and time it deserves. Let those moments develop naturally without rushing.
• Enhance Your Descriptions : Make your imagery more vivid to help the reader visualize your story. For example, instead of just saying, “The room was noisy,” you could say, “The room buzzed with excited chatter.” These small tweaks can make your story feel more alive and engaging.

Step 5. Adding Personal Touches

As you polish your personal narrative, focus on making it uniquely yours. You can include personal reflections on your experiences. For example, if you’re writing about a challenging project, discuss not just the struggle but how it impacted you personally and professionally.

Besides, add unique details that only you can share. Instead of generic descriptions, use specific anecdotes or sensory details, like how the scent of freshly baked cookies from your grandmother's kitchen made you feel nostalgic.

Last but not least, incorporate dialogues or direct quotes from people involved in your story to add authenticity and depth. For instance, if your mentor gave you advice, include their exact words to capture the moment’s impact. This approach will help you understand how to write a personal narrative that is both engaging and deeply personal.

Not sure where to begin? You can always buy a narrative essay from experts who can help shape your story.

Step 6: Editing for Clarity and Style

When you’re editing your personal narratives, the goal is to make sure everything flows smoothly and makes sense. Here’s how to get it just right:

• Clarify Your Message: Check for any parts of your story that might be a bit confusing. If you talked about being excited about a project and then suddenly shifted to its challenges, make sure to connect these thoughts clearly. For instance, you might rephrase it as “I was excited about the project, but I soon faced some unexpected challenges, like tight deadlines.”
• Simplify Complex Sentences: Break down long or complicated sentences. Instead of saying, “My enthusiasm for the project, which was incredibly high despite the difficulties I faced, was the driving force behind my perseverance,” you could simplify it to, “Even though the project was tough, my excitement kept me going.”
• Smooth Transitions: Check how your paragraphs and sections flow together. If you jump from describing a problem to the solution without a clear link, add a transition. For example, “After struggling with the project’s challenges, I realized that asking my mentor for help was the key to overcoming the obstacles.”

Oh, and read your narrative out loud. This can help you spot any awkward phrases or spots where the story might be a bit choppy. It’s a great way to catch any issues and make those final tweaks to get everything just right.

Personal Narrative Prompts

Here are ten personal narrative prompts to get you thinking about different moments in your life:

Need more tips on how to get started? Check out this guide on how to start a narrative essay to kick off your writing with a strong opening.

Personal Narrative Examples

Here are a few personal narrative beginnings to spark your creativity. These snippets are designed to get you started and inspire your own storytelling.

Wrapping Up

As you finish up your story, think about how those moments shaped who you are today. It's not just about what happened, but how it changed you. When learning how to write a personal narrative, it’s important to focus on the moments that truly matter to you and tell them in your own voice. This way, your narrative can really connect with others. 

Remember, the best stories come straight from the heart, so trust yourself and let your experiences shine through!

If you're working on a personal statement, you might want to explore a personal statement service that can help you create a compelling narrative.

Turn Memories into Masterpieces

Let us transform your experiences into a beautifully crafted narrative that stands out and makes an impact.

How to Start a Personal Narrative?

Can a personal narrative be about anything, what is the format of a personal narrative.

Daniel Parker

is a seasoned educational writer focusing on scholarship guidance, research papers, and various forms of academic essays including reflective and narrative essays. His expertise also extends to detailed case studies. A scholar with a background in English Literature and Education, Daniel’s work on EssayPro blog aims to support students in achieving academic excellence and securing scholarships. His hobbies include reading classic literature and participating in academic forums.

is an expert in nursing and healthcare, with a strong background in history, law, and literature. Holding advanced degrees in nursing and public health, his analytical approach and comprehensive knowledge help students navigate complex topics. On EssayPro blog, Adam provides insightful articles on everything from historical analysis to the intricacies of healthcare policies. In his downtime, he enjoys historical documentaries and volunteering at local clinics.

• The New York Times. (2020, January 7). Personal Narrative Essay Winners. The New York Times. https://www.nytimes.com/2020/01/07/learning/personal-narrative-essay-winners.html